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Introduction: The aim of this study was to assess the nutritional effect of a peanut based 
ready-to-use food supplement (RUSF) [Sibusiso®] on HIV positive adults on antiretroviral 
therapy (ART). 
Objectives:  (1) To determine whether the BMI of HIV positive adults on ART supplemented 
with RUSF was improved after a three months supplementation period.  (2) To determine the 
most predominant self reported disease symptoms experienced by HIV positive adults on 
ART at baseline assessment. (3) To determine whether predominant disease symptoms 
experienced by HIV positive adults in ART improved after supplementation with Sibusiso® 
RUSF.  (4) To determine whether appetite, meal consumption and energy levels improved 
among HIV positive adults on ART supplemented with Sibusiso® RUSF.  (5) To determine if 
there was any observed changes in body fat distribution in HIV positive adults on ART after 
being supplemented with Sibusiso® RUSF.   
Materials and methods: This is a non randomised descriptive study whereby data was 
collected using a cross-sectional method.  It included 50 HIV positive adults (between 20 and 
78 years of age) on antiretroviral therapy, attending the 1000 hills community helpers’ centre, 
Durban, KwaZulu-Natal. A monitoring tool was used to collect data on anthropometrical 
measurements (weight and height), disease symptoms experienced, disease conditions 
identified by the researcher/research assistants, level of appetite, meal frequency consumption 
and energy for each subject for a period of three consecutive months.  Twenty participants 
were interviewed to assess the body fat distribution after using the supplement using a self 
reporting method. 
Results and discussions: Study findings suggest that supplementation with RUSF for at least 
three months has a potential to gradually improve weight gain among HIV-positive adults on 
ART.  The most self reported predominant disease symptom experienced before 
supplementation was fever, followed by nausea and persistent diarrhoea.  This was in keeping 
with the results from other studies.  After supplementation, there was a significant 
improvement in fever and gastroenteritis and steady but statistically significant decline in 
vomiting.  However there was non-significant improvement in nausea and no change in 
persistent diarrhoea.  RUSF in this study was also found to exert a beneficial effect on 
appetite, meal consumption and energy levels of participants.  The study showed that short-
term supplementation with RUSF is highly unlikely to result in lipodystrophy. 
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Conclusion: The administration of the nutrition supplement Sibusiso® RUSF for at least 
three months, in conjunction with the use of ART, was found to improve nutritional status in 
HIV patients under the controlled condition.  Sibusiso® RUSF was able to improve the 
episode of fever which was most dominant disease symptom at baseline while improving 
gastroenteritis and vomiting.  However it did not have an impact on reducing the episodes of 
nausea and persistent diarrhoea.  Sibusiso® RUSF was also able to improve appetite, meal 
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CHAPTER 1   
INTRODUCTION, THE PROBLEM AND ITS SETTING 
 
1.1  Importance of the study 
 
Human Immunodeficiency Virus (HIV) is a retrovirus that infects cells of the immune system 
and impairs the body’s natural defence against disease and infection (United State Agency of 
International Developments [USAID] 2001).  The most advanced stage of HIV is known as 
Acquired Immune Deficiency Syndrome (AIDS) (USAID 2001), which has become the most 
deadly disease mankind has ever faced (Joint United Nations Programme on HIV/AIDS 
[UNAIDS] 2001).  This disease is currently not curable anywhere in the world, therefore, an 
individual diagnosed with HIV has a lifetime of disease to management (UNAIDS 2001).  
According to the UNAIDS (2013) report, worldwide, 35.3 (32.2–38.8) million people were 
estimated to be infected with HIV in 2012.  However, the number of AIDS deaths had 
declined by 1.6 (1.4–1.9) million AIDS deaths in 2012, down from 2.3 (2.1–2.6) million in 
2005.  This report further stipulates that the Sub-Saharan Africa region host the world’s worst 
HIV/AIDS epidemic and HIV is now defined as one of the major public health concerns in 
the region.   This is despite the 34% reduction in an annual number of new infections in the 
region since 2001.  Approximately 6.1 million of South African people were HIV infected in 
2012, an increase from 4.3 million in 2002 (UNAIDS 2013), with young adults living in 
informal settlements being the most vulnerable group (UNAIDS 2013; O’Hara, Garbharran, 
Edwards & Smith 2003).  Although there is a reported global decrease in estimated AIDS 
deaths, an estimated 240 000 deaths were reported in South Africa, an increase from 200 000 
in 2001 (UNAIDS 2013). 
 
The major identified challenges with HIV and AIDS is that it is often accompanied by poor 
nutritional status of those infected or affected (Anabwani & Navario 2006).  Hence, the South 
African government developed an operational plan for comprehensive HIV/AIDS care 
management and treatment (DoH 2003).  Nutrition care and support (NCS) was integrated 
into this plan with the purpose of improving nutritional status of HIV infected individuals 
(Ncayiyana 2007).  This plan thus enabled South Africans to access a full array of 
interventions including nutrition related interventions (nutrition assessment and counselling, 
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and food supplements when it is necessary) at an early stage (DoH 2003).  According to the 
recently updated guidelines emanated from the plan, antiretroviral therapy (ART) will be 
initiated in adults and adolescents with the CD4+ cell counts ≤350/mm
3 
(DoH 2010).  
According to the UNAIDS global report (2013) the number of people receiving antiretroviral 
treatment in South Africa reached more than 2.15 million in 2012. 
 
Malnutrition, including both overnutrition and undernutrition, is a health problem directly and 
indirectly contributing towards high rates of morbidity and mortality globally, but more 
particularly in developing countries (Müller & Krawinkel 2005).  South Africa is faced with a 
double burden of diseases, with a high prevalence of both under- and overnutrition (Vorster 
2010; Faber & Wenhold 2007).   In Sub Saharan Africa, HIV has been associated with 
worsening malnutrition, characterized by substantial weight loss and high prevalence of 
underweight (Nnyepi 2009).  There are several other factors contributing to higher risk of 
undernutrition in people living with HIV/ AIDS (PLWHA) which include reduced food intake 
(due oral thrush and/or vomiting), physiological/functional changes, the presence of 
opportunistic infections, and side effects (such as loss of appetite, nausea, and diarrhoea) from 
the HIV/AIDS/TB medication (Maldey, Haile & Shumye 2014; Regional Centre for Quality 
of Health Care (RCQHC) 2004; Piwoz & Preble 2000; Semba & Tang 1999).   Other factors, 
such as adverse socioeconomic conditions, poor housing conditions, water supply and 
sanitation also contribute to the problem of malnutrition (Hailemariam, Bule & Ayele 2013; 
Sguassero, Onis, Carroli 2010).  South Africa is faced with a double burden of disease, with a 
high prevalence of both under- and overnutrition (Vorster 2010; Faber & Wenhold 2007).   
Although nutrition has a role to play in the overall management of HIV (Ncayiyana 2007), to 
date there are very little published scientific literatures on strategic interventions on the 
overall management of HIV.  Therefore, the lack of nutrition related studies in South Africa 
targeting PLWHA is a concern.  
 
Ready-to-use supplementary foods (RUSFs) were originally developed to reduce the 
incidence of malnutrition and treat malnutrition among children and adults (Scherbaum, 
Shapiro, Purwestri, Inayati, Novianty, Stütz, Yusran, Müller, Wirawan & Suryantan 2009; 
World Health Organization (WHO) 2007).  RUSFs as a perceived solution to malnutrition 
worldwide (Scherbaum et al 2009), were made available in various forms such as compressed 
bars, biscuits and micronutrient powders, lipid-based nutrient supplements, and high-quality 
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vegetable oil and pastes (de Pee & Bloem 2009).  A RUSF called Sibusiso® is a peanut and 
soya paste fortified with micronutrients and macronutrients that was developed by the South 
African non-governmental organization (NGO), the Gift of the Givers Foundation (GOTG) in 
more or less a decade ago (Gift of The Givers 2010).  Sibusiso® RUSF was primarily used for 
prevention of weight loss and resulting malnutrition before the implementation of the first 
South African National Comprehensive HIV and AIDS Treatment programme.  Even though 
there was no scientific backing to its success, there was a huge demand for it in the market 
(Pronsky, Meyer & Fields-Gardner 2001).   
Since nutrition intervention remains important in the management of HIV, Sibusiso® ready-
to-use supplementary food is still used.  Sibusiso® RUSF has been claimed to benefit 
individuals under a variety of pathological conditions, including malnutrition, HIV and TB 
(GOTG 2010; Appendix A).  However, up to now all evidence regarding its affectivity is 
anecdotal in nature.  Besides that, several studies have been done on the effectiveness of 
pharmaceutical supplements (Friis 2005; Fawzi, Msamanga, Spiegelman, Kapiga, Villamor, 
Mwakagile, Mugusi, Hertzmark, Essex, Hunter 2004; Kupka & Fawzi 2002) and corn based 
supplements on nutritional status (Ndekha, van Oosterhout, Zijlstra, Manary, Saloojee & 
Manary 2009),  but thus far there are still limited published studies on the impact of 
peanut/soya milk based pastes enriched with micronutrients supplements on HIV positive 
adults on ART.  It is therefore important to scientifically determine the success of peanut 
based supplementation being implemented on HIV positive adults on ART. The present study 
will provide clinical evidence based on scientific research, under controlled condition and on 
adult population.   
 
1.2  Background on the 1000 hills community helpers’ centre 
 
The 1000 hills community helpers’ centre provides services to people of Inchanga, Fredville 
and surrounding areas.  The 1000 hills community helpers’ centre was established in 1989 
initially as a community feeding programme.  In 1990 it was realized that community 
members were in need of medical assistance due to the impact of HIV/Aids related illnesses. 
It was then decided to start up a basic clinic followed by an infant nutritional program. 
Medical volunteers were subsequently sourced to assist in providing this service, later joined 
by a pediatrician as well as five registered nursing sisters.  In response to the needs of the 
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community, it was converted to community care centre in 2008 comprising of a health and 
wellness clinic, children’s infirmary, education and development facility.  The main services 
that are offered at present are HIV treatment, clinics, a feeding scheme, counselling, home-
based care, and the support groups. 
 
1.3  Statement of research problem 
 
Sibusiso®, a peanut/soya based ready-to-use supplementary food with a potential to be a 
relevant and effective nutrition intervention for Africa, has been used widely with growing 
anecdotal evidence of it success.  The main research question is whether giving Sibusiso® 
RUSF will have any beneficial effect on improving the disease condition on HIV positive 
adults on ART attending 1000 hills community helpers’ centre, Durban, KwaZulu Natal.    
Supplementing HIV positive patients with a Sibusiso® RUSF was envisaged to help provide 
optimum nutrition, promote weight gain, and as a result alleviate the burden of malnutrition 
and complications that are associated with the poor nutritional status.   
 
1.4 Study design 
 
This research is a descriptive study whereby data was collected using a non-randomised 
cross-sectional method.  The study was conducted in year 2012 on 50 participants.  It 
included of forthy-four female and six male adults on antiretroviral therapy.  Participants were 
between the age of 20 and 78 years living in Inchanga, Fredville and surrounding areas, 
KwaZulu-Natal, attending the 1000 hills community helpers’ centre.  Participants were 
supplemented with Sibusiso® RUSF for a period of three months.   
 
1.5   Objectives of the study 
 
The objectives of this study were to: 
1.5.1 determine whether the Body Mass Index (BMI) of HIV positive adults on ART 
supplemented with Sibusiso® RUSF was improved after a three months 
supplementation period. 
1.5.2 determine the most predominant self reported disease symptoms experienced by HIV 
positive adults on ART at baseline. 
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1.5.3 determine whether predominant disease symptoms experienced by HIV positive adults 
on ART improved after supplementation with Sibusiso® RUSF.  
1.5.4 determine whether appetite, meal consumption and energy levels improved among HIV 
positive adults on ART supplemented with Sibusiso® RUSF. 
1.5.5 determine if there was any observed changes in body fat distribution in HIV positive 




The hypotheses of this study were as follows: 
1.6.1 Sibusiso® RUSF will contribute to an increase in the BMI of HIV positive adults on 
ART after a three months supplementation period. 
1.6.2 Diarrhoea, nausea and vomiting will be the most predominant self reported disease 
symptoms experienced by HIV positive adults on ART at baseline as a result of the 
diseases. 
1.6.3 Sibusiso® RUSF will improve the predominant disease symptoms experienced by HIV 
positive adults on ART improved after a three months supplementation period. 
1.6.4 Sibusiso® RUSF will improve appetite, meal consumption and energy levels among 
HIV positive adults on ART after a three months supplementation period. 
1.6.5 There will be no observable changes in body fat distribution in HIV positive adults on 
ART after being supplemented with Sibusiso® RUSF. 
 
1.7   Study limitations 
 
The limitations were imposed by the slightly poor adherence to the supplementary 
programme, nevertheless the study was planned as an “intention-to-treat” study.  The majority 
of men were not compliant with the intervention to be part of the data to be analysed since 
their visits were inconsistent, non-consecutive and they withdraw early.  This resulted in 
gender imbalance and a reduced sample size.  Although the current study assessed the 
frequency of consumption of certain foods for the purpose of identifying dietary practices, it 
was unable to measure dietary intake at recruitment or during intervention.  Hence, the current 
study did not have information on average intake of energy, the micronutrient and 
macronutrients composition of baseline diet or information on energy received from 
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household foods.  This was going to reveal the extent to which normal eating pattern of the 
participants possible factored into weight gain.  
1.8 Study parameters and general assumptions 
 
In order for the hypotheses of this study to be tested successfully, it was assumed that:  
       Sibusiso® RUSF was provided in addition to other meals and did not replace any 
of the meals in order to promote weight gain;   
       Participants did not have any other disease conditions or symptoms other than that 
identified by the monitoring tool during the supplementation period; and 
       None of the participants had nut allergies.  
 
1.9. Operational Definitions 
 
 Antiretroviral drugs: Drugs that act against a retrovirus by almost completely 
suppressing its replication at different stages of its life cycle (Stedman 2008).  
 Fever: An abnormal elevation of body temperature in response to some disease or illness. 
A fever may be accompanied by symptoms such as shivering, headache, sweating, thirst, 
faster-than-normal breathing and a flushed face (Peters 2007).  
 Gastroenteritis: Inflammation of the digestive track particularly the stomach and 
intestines, usually causing sudden upsets that last for two or three days. Appetite loss, 
nausea, vomiting and diarrhoea are the usual symptoms (Peters 2007). 
 Lipodystrophy: a change in body fat distribution in the body which can be in two forms, 
which include lipohypertrophy which referred to a generalized fat gain in the specific area 
and lipoatrophy referred to a generalized fat wasting in the specific areas (Leach-Lemens 
2009).   
 Macronutrients: For the purposes of this study, macronutrients refer to carbohydrate, fat, 
and protein.  
 Malnutrition: Imbalance, excess or lack of proper nutrient consumption leading to 
overnutrition or undernutrition [World Food Programme (WFP) 2012].  




 Nutritional status: The nutritional health of a individual as determined by anthropometric 
measurements (weight, height, etc), biochemical measurements of nutrients, physical 
examination and/or a dietary analysis (DoH 2007). 
 Opportunistic infections: Infections that are more frequent or severe due to 
immunosuppression, especially in the presence of diseases such as HIV (Aidsinfo 2008) 
 Oral thrush: A fungal infection caused by Candida albicans that affects the mouth, 
characterized by painless, creamy white, plaque-like lesions of the tongue surface (Peters 
2007).  
 Ready-to-use supplementary food: High energy peanut based pastes fortified with high 
levels of nutrients during processing, higher than in the normal fortification process, it is 
used for the prevention of acute malnutrition or chronic malnutrition (Latham, Jonsson, 
Sterken & Kent 2011). 
 Ready-to-use therapeutic food: A generic term of high energy and nutrient-dense food or 
food product designed to provide similar nutritional profile as that of the F-100 therapeutic 
milk.  It is generally used in a rehabilitation treatment phase of severe acute malnutrition as 
a sole source of food except for water or breastmilk (Latham et al 2011; Collins & Sadler 
2002).  
 Supplementary feeding: The provision of extra food to children or families beyond the 
normal ration of their home diets (Sguassero, de Onis & Carroli 2005)  
 Medication side effects: Any reaction to or consequence of a medication or therapy. 
Usually, although not necessarily, the effect is undesirable and may manifest itself as 
nausea, dry mouth, dizziness, blurred vision, discoloured urine or tinnitus (Anderson 
2009).  
 Tuberculosis (commonly referred to as TB): Occurs when a susceptible individual 
inhale a nuclei droplet containing the bacterium Mycobacterium tuberculosis. The primary 
infection is usually asymptomatic (Latent TB infection).  Progressive infection in lungs 
causes coughing (sometimes with blood stained sputum), chest pain, shortness of breath, 










AI Adequate intake 
ART Antiretroviral therapy 
ARV        Antiretroviral drugs 
BMI Body Mass Index 
CVD Cardiovascular diseases 
DoA Department of Agriculture 
DoH Department of health 
DRI Dietary Reference Intake 
FAO Food and Agriculture Organization 
GOTG Gift of the Givers Foundation 
FIVIMS       Food Insecurity and Vulnerability Information Mapping System 
HAART Highly Active Antiretroviral Therapy 
HIV/AIDS       Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome 
HSRC Human Science Research Council 
INP         Integrated Nutrition Programme 
IRR Incidence Rate Ratio 
KZN                 KwaZulu-Natal 
LBM Lean Body Mass 
LDS Lipodystrophy Syndrome 
NGO             Non-Governmental Organisation 
PEM             Protein-Energy Malnutrition 
PLWHA         People Living With HIV/AIDS 
RDI Recommended Dietary Intake 
REE Resting Energy Expenditure 
RUSF        Ready-To-Use Supplementary Food 
RUTF            Ready-To-Use Therapeutic Foods 
SPSS             Statistical Package for Social Sciences 
StatsSA Statistics South Africa 
TB                Tuberculosis 
UKZN University of KwaZulu-Natal 
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UNAIDS          Joint United Nations Programme on HIV/AIDS 
UNICEF        The United Nations Children's Fund 
USAID          United States Agency for International Development 
WHO            World Health Organization 
WFP              World Food Programme 
  
 
 1.11 Summary  
 
The prevalence of malnutrition in South Africa is high and impact greatly on mortality and 
morbidity. Confounding the problem of malnutrition is HIV infection which is highly 
prevalent among the poor and further contributes to poor survival. Appropriate nutrition 
interventions aimed at decreasing the rates of malnutrition are required. RUSFs among other 
benefits, have been found to have positive effects on weight gain among malnourished 
patients. Hence, this study aimed to determine whether a Sibusiso® RUSF produced by the 
Gift of the Givers Foundation would promote weight gain among HIV adults on ART. The 
participants included in this study were from a community of low socio-economic status.  By 
supplementing PLWHA for a period of three months, the RUSF could promote weight gain, 
reduce disease symptoms, improve appetite, and thereby alleviate the burden of malnutrition. 
 
1.12 Outline of the dissertation 
 
The layout of the dissertation is as follows: 
Chapter 1: Introduction, the problem and its setting 
Chapter 2: Literature review 
Chapter 3: Methodology 
Chapter 4: Results 
Chapter 5: Discussion 
Chapter 6: Conclusions and Implications for further research 
 
This dissertation was referenced according to the guidelines used in the Programme of 








In this chapter the prevalence of HIV globally and in South Africa, interaction between 
nutrition and HIV/AIDS, the factors that contribute to malnutrition, the nutritional status and 
nutritional needs of HIV infected patients will be reviewed.  Available long and short term 
strategies developed to alleviate malnutrition in PLWHA will be reviewed.  At the end, the 
effect of Sibusiso® RUSF on nutritional status, diseases symptoms and on body fat 
distribution will also be reviewed. 
 
2.2. Prevalence of HIV globally, and in South Africa 
 
UNAIDS (2013) reported that in 2012 an estimated 35.3 (32.2–38.8) million people were 
living with HIV globally.  There was a notable sharp decline in new infections globally, from 
3.4 (3.1–3.7) million in 2001 to 2.3 (1.9–2.7) million in 2012.  At the same time the number 
of AIDS deaths also declined from 1.6 (1.4–1.9) million AIDS deaths in 2012, down from 2.3 
(2.1–2.6) million in 2005.  The report further stipulates that the far largest concentration of 
HIV/AIDS is in the developing world and Sub-Saharan Africa in particular where more than 
70% of the population were affected in 2012.  UNAIDS (2013) revealed that despite this 
devastating condition, sub-Saharan Africa has achieved a notable reduction (approximately 
37%) in HIV prevalence between 2001 and 2012.  Even with these favourable trends, HIV 
prevalence among young women remains more than twice as high as among young men 
throughout sub-Saharan Africa.  UNAIDS (2013) further stipulates that in South Africa, HIV 
infection increased from 4.3 million to 6.1 million between 2001 and 2012.  In addition, the 
number of HIV deaths increased from 200 000 to 240 000 between 2001 and 2012.  Global 
AIDS response progress report (2012) documented that there is a wide variation in HIV/TB 
prevalence by age, race, gender, socio-economic status and geographical location.  This report 
specified that in the past twenty years, among nine provinces of South Africa, KwaZulu-Natal 
was the most affected among the 15-49 year olds and the HIV prevalence remained stable at 




2.3. Food security, nutrition and HIV/AIDS 
 
The HIV/AIDS epidemic is having an extensive effect on health, nutrition, food security and 
overall socioeconomic development in countries that have been greatly affected by the disease 
(WHO 2003).  According to the South African government, food security “is achieved when 
all people, at all times, have physical, social and economic access to sufficient, safe and 
nutritious food, to meet their dietary needs and food preferences for an active and healthy 
life” (Department of Agriculture [DoA] 2002).  In sub-Saharan Africa where HIV has reached 
epidemic, 400 million people were threatened by food insecurity by the turn of the 21
st
 
century (Hattingh, Walsh, Veldman, Bester 2007; Steyn & Walker 2000).  In 2004, the 
Human Science Research Council (HSRC) as cited by [Development Bank of Southern Africa 
(DBSA) 2008] estimated that 14 million South Africans were food insecure.  The HSRC 
(2005) reported on the survey conducted in Sekhukhune to pilot the development of a food 
insecurity and vulnerability modelling system (FIVIMS) for South Africa. The report revealed 
that South Africa is producing enough food to feed its population.  However, there is still a 
large scale of hunger, even with a decline in South African households vulnerable to hunger 
over the past decade from 23.8 to 11.5 between 2002 and 2011 (Statistics South Africa 
[StatsSA] 2012).  Furthermore, a number of households did not have a diet that is diverse to 
allow for optimal nutritional status (StatsSA 2012).  In settings where poverty and lack of 
access to care prevails, malnutrition also becomes prevalent (Nnyepi 2009).  WHO (2003) 
reported that the HIV/AIDS epidemic also seem to be disturbing in populations where 
malnutrition is already an endemic.  Semba & Tang (1999) stipulated that HIV and poor 
nutrition form part of a typical vicious cycle compounded by the emergence of micronutrient 
deficiencies, malnutrition-related immune suppression, and oxidative stress increasing the 
susceptibility to faster disease progression and high mortality rate (See figure 2.1 below 




Figure 2.1: Cycle of HIV/AIDS and malnutrition (Semba & Tang 1999) 
The HSRC (2005) report stipulated that in the post apartheid era, urbanisation and declining 
agrarian activities have been profound and had transformed the South African economy into a 
wage economy with most citizens accessing food via purchase rather than producing food for 
themselves.  Even in rural areas, most households’ access to food is partially or wholly reliant 
on household income.  According to Polzer and Schuring (2003) malnutrition persists due to 
poor access to food by certain parts of the population and not as a result of overall shortage of 
food in the country.  Among the poor who by definition are characterised by unemployment, 
the majority of income is accrued in the form of insecure/informal jobs, the government social 
welfare safety net of old age pensions and child support grants, and private transfers from 
working relatives and neighbours (DoA 2002).  As a result, food security is largely influenced 
by direct or indirect access to cash in order to purchase food.   
The persistence and severity of poverty and food insecurity is directly or indirectly aggravated 
by the HIV pandemic which in turn increases the risk of intergenerational malnutrition 
(Hailemariam et al 2013; Theodore 2009; Department of Health [DoH] 2007).  An 
interwoven relationship between poverty and HIV/AIDS has been noted; they have a complex 
bidirectional relationship that has been proven over the years (Theodore 2009).  The Food and 
Agricultural Organisation (FAO) (2008) stated that HIV/AIDS normally affects the 
household’s most productive members first.  When these individuals become ill, their ability 
to work, feed themselves and provide care to their families become compromised.  When HIV 
has affected the family economy factor, food and nutrient intake consequently become 
adversely affected and the disease progresses even further (Hailemariam et al 2013).  As the 
13 
 
disease progresses further, resources are drained.  For example, valuable assets may need to 
be sold in order to pay for food and medical expenses, and adoption of harmful coping 
strategies such as children dropping out of school, all contribute to poverty advancement 
(Theodore 2009).  As a result of living in poverty, individuals with HIV sometimes adopt 
risky behaviours such as sex work in order to generate income as another coping strategy 
which further exacerbates the spread of HIV and obviously malnutrition (FAO 2008).  
In 2002 South Africa adopted an integrated food security strategy aimed at eradicating 
hunger, malnutrition and food security by 2015.  One of the strategic objectives is to improve 
nutritional status (DoA 2002).  WHO (2003) suggested that in spite of existing food 
insecurity, interventions aimed at improving the nutrition of PLWHA should be based on 
sound scientific evidence, local resources, and programmatic and clinical experience with the 
prevention, treatment, and management of the disease and related infections.  WHO (2003) 
further acknowledged the gaps in available scientific knowledge regarding the interventions 
aimed at improving the nutrition of PLWHA.  This justifies a need for the study on RUSFs 
since it is an intervention with a lot of resources invested in it. 
 
2.4. Nutrition and immunity in HIV/AIDS 
 
Nutrition has been a important factor in the management of HIV infection since early in the 
history of HIV/AIDS epidemic (Hattingh et al 2007).  Hence, the relationship between 
nutrition and HIV has gained substantial attention from scientists and PLWHA.  The main 
objective in the emphasis of nutrition in the management of HIV/AIDS is to maintain weight 
and strengthen the immune system (South African HIV Clinicians Society Expert Committee 
2004).  Malnutrition and HIV compromise the immune system which ultimately facilitates 
disease progression and affects the overall clinical outcome (Hailemariam et al 2013).  
Therefore, malnutrition plays a major role in HIV related mortality and morbidity, as well as 
the functional status and overall quality of life (Hailemariam et al 2013; Hattingh et al 2007). 
Conversely, optimal nutrition has been shown to have positive impact on immunity with some 
nutrients associated with antibody production and reducing susceptibility to co-infection such 




According to UNAIDS (2013), tuberculosis remains the leading cause of death among 
PLWHA.  Globally, PLWHA accounted for 1.1 million (13%) of the estimated 8.7 million 
individuals who globally developed tuberculosis in 2012.  Of the 2.8 million people with 
tuberculosis who received an HIV test result in 2012, 20% tested HIV-positive.  The report 
further stipulates that 42% of those who tested HIV positive were from the sub-Saharan 
Africa.  Frieden, Sterling, Munsiff, Watt and Dye (2003) reported that the increasing 
prevalence of HIV/TB co-infection is of concern in Africa with more than 60% contributed by 
Botswana, Zambia, Zimbabwe and South Africa.  South Africa is the leading African country 
with 2 million co-infected adults which is double the number of the second leading country 
(WHO 2011).  UNAIDS (2013) revealed that the world has made substantial progress towards 
reducing the prevalence of TB related mortality, with a notable 36% decline between 2004 
and 2012.  However in South Africa, change in TB related deaths among PLWHA during the 
same period was approximately 11.1%.  In addition, TB was reported to be the leading cause 
of death for PLWHA in 2011. 
South Africa’s challenge of the HIV/TB co-infection pandemic is also coupled with 
malnutrition referred to as “triple trouble” (Chaparro & Diene 2009).  Provinces which are 
most affected with a high percentage of co-infected individuals are; KwaZulu-Natal, Gauteng 
and Mpumalanga because of the fast-growing rate of the HIV infection (Fourie 2006).  TB-
related illnesses can also contribute to malnutrition due to increased nutrient requirements 
(Saunders, Smith & Stroud 2011).  In South Africa HIV and TB services have been integrated 
(UNAIDS 2013).  The number of PLWHA and receiving ARVs increased to more than 2.5 
million in 2012 and all PLWHA received screening for TB at every clinic visit (UNAIDS 
2013).  Moreover, the best possible intervention that will address malnutrition, strengthen the 
immune system and reduce the risk of co-infection with opportunistic infections is 
fundamentally required. 
 
2.5. Changes in anthropometric status and nutritional status of HIV infected adults 
 
When HIV was first discovered, it was labelled a slim disease, since weight loss was a 
prominent feature of the disease (Marston & De Cock 2004).  Weight loss is still associated 
with progression of HIV infection (Onyango, Walingo, Mbagaya & Kakai 2012; Wheeler, 
Gibert, Launer, Muurahainen, Elion, Abrams & Bartsch 1998).  Bartlett, Hirsch & Mitty 
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(2013) reported that there is uncertainty whether weight loss is a cause of progression or a 
marker of disease severity.  However, it has been suggested that weight loss/wasting cannot 
be an effect of HIV per se but an end result of opportunistic infections.  Macallan, Noble, 
Baldwin, Foskett, McManus & Griffin (1993) stated that weight may remain stable even if the 
patient is not on ART.  However, weight recovery is still achieved with the best possible 
treatment of infections.   
Body mass index (BMI) is used to determine a healthy body weight and is calculated by 
dividing the patient’s weight (kg) by height squared (m
2
) (Venter, Gericke & Bekker 2009).  
The South African HIV Clinicians Society Expert Committee (2004) stated that a BMI of less 
than 18.5 kg/m
2
 is an independent predictor of a high mortality risk.  Hence, BMI is assessed 
and recorded at each clinic visit as part of malnutrition risk identification.  Babameto & 
Kotler (1997) reported that weight loss is often the event that begins a vicious circle of 
increased fatigue and a decrease in physical activity, including the inability to prepare and 
consume food by the patient living with HIV/AIDS.  A weight loss of more than 10% of 
initial body mass has been associated with a decline in physical performance, and 20% weight 
loss is associated with hospitalisation (South African HIV Clinicians Society Expert 
Committee 2004).   
Weight loss and wasting in AIDS patients are multi-factorial in etiology, with inadequate 
intake, nutrient malabsorption and metabolic disturbance as most prominent determinants 
(South African HIV Clinicians Society Expert Committee 2004).  HIV related wasting 
typically follows two patterns, which are the slow and persistent weight loss from anorexia 
and gastrointestinal disorders, and a rapid, intermittent weight loss from secondary infections 
(Macallan 1999).   
The first type of HIV-related wasting syndrome is described as starvation-related wasting 
resulting from consistent voluntary or involuntary food deprivation in patients who have not 
manifested opportunistic infections (South African HIV Clinicians Society Expert Committee 
2004).  Patients presenting with this type of wasting react positively to nutrition support and 
feeding which typically reverse starvation (South African HIV Clinicians Society Expert 
Committee 2004).   
The second type of HIV related wasting is typical of cachexia, characterized by a predominant 
loss of lean body mass caused by alteration of metabolism (South African HIV Clinicians 
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Society Expert Committee 2004).  Cachexia has been described as one of the major causes of 
morbidity and mortality in relation to HIV infection (Castetbon, Kadio, Bondurand, Boka 
Yao, Barouan, Coulibaly, Anglaret, Msellati, Malvy & Dabis 1997). The South African HIV 
Clinicians Society Expert Committee (2004) described this type of wasting as a condition that 
prevails during stress states such as sepsis, trauma, or surgery.  This is a type of wasting is 
irreversible by solely food intake or feeding as an intervention (South African HIV Clinicians 
Society Expert Committee 2004; Macallan 1999).  Macallan (1999) stated that therapeutic 
strategies do not reverse depletion of lean body mass (LBM), but have been reported to 
mainly increase body fat and water. 
According to Salomon, de Truchis and Melchior (2002), “It is critically important to identify 
and characterize early risk factors for wasting in HIV infected patients and to monitor wasting 
with a standardized set of strategies for diagnosis, surveillance and appropriate treatment”  
 
2.6. Factors that contribute to HIV/AIDS related malnutrition 
 
The following section will review the factors that lead to malnutrition in HIV/AIDS.  These 
factors include decreased nutrient intake, nutrients malabsoption, metabolic alteration and 
depletion of antioxidant nutrients.  
2.6.1. Insufficient nutrient intake and increased nutrient losses 
In all stages of HIV infection, emphasis is placed on a healthy eating pattern and a balanced 
diet (WHO, FAO 2002; USAID 2001).  An unbalanced diet deficient in macronutrients can 
result in a decreased energy intake (Macallan 1999) and ultimately weight loss (USAID 2001; 
Macallan 1999).  Decreased food intake can result in severe loss of body cell mass and 
ultimately to death (Madley, Haile & Shumye 2014).  
There are several reasons for an inadequate nutrient intake in HIV disease (Gramlich & 
Mascioli, 1995).  MacArthur & DuPont (2012) reported that nausea and vomiting are 
common complications among patients with HIV infection and AIDS, since the 
gastrointestinal tract is a primary target during an episode of acute infection.  According to 
WHO, FAO (2002), nausea and vomiting impede adequate food intake.   Nausea is suggested 
to be caused by multiple factors, such as infection, dehydration, stress, certain foods and it 
can also be a side effect of certain medications including ARVs (WHO, FAO 2002).  Other 
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serious gastrointestinal disorders such as pancreatitis and malignancies are very rare 
(MacArthur & DuPont 2012).  Anorexia, central nervous system disease, dysphagia and 
odynophagia are among other factors that may affect micronutrient intake during HIV 
infection, resulting in failure to meet dietary requirements (USAID 2001; Semba & Tang 
1999).   
Fever is a common complication in HIV infected individuals, possibly caused by a 
compromised immune system due to infection (WHO, FAO 2002).  In the study conducted by 
Ahoua, Umutoni, Huerga, Minetti, Szumilin, Balkan, Olson, Nicholas, Pujades-Rodríguez 
(2011) in Uganda and Kenya, findings were that at study enrolment, among the most 
frequently diagnosed opportunistic infections, fever of unknown aetiology was evident.  
WHO, FAO (2002) put forward the fact that fever increases the demand for energy and 
nutrients which are both fundamental in fighting the infection.  However, fever and 
commonly occurring infections reduce the intake of food in HIV positive patients by altering 
the patient’s appetite (USAID 2001).  According to Saunders & Smith (2010), a reduction of 
food intake is the most distracting factor in the management of disease-related malnutrition.  
Reduction of food intake weakens the immune system and increase susceptibility to 
opportunistic infections such as TB.  Opportunistic infection such as TB results in changes in 
the secretion of cytokines, glucocorticoids, peptides, insulin and insulin-like growth factors 
which also leads to loss of appetite and ultimately reduce food intake (Avert 2011; Saunders 
et al 2011; Suttajit 2007).   In a study conducted by Castetbon et al (1997) in HIV-infected 
outpatients in Abidjan, Côte D’Ivoire, West Africa, 45 percent of symptomatic patients 
particularly reported appetite related problems.  Patients who reported appetite related 
problems also demonstrated an impaired anthropometric status (Castetbon et al 1997).   
A RCQHC (2004) report stated that poor appetite can be a side effect of ARV drugs such as 
zidovudine (ZDV), lamivudine (3TC) and stavudine (d4T).  Appetite can also be influenced 
by the perceived smell and taste of food, especially in older individuals since the sensitivity to 
sensory property declines with age (Zandstra & de Graaf 1998).  Other conditions such as 
Herpes simplex, aphtous ulcers, or cytomegalovirus may lead to smell and taste alterations 
(Babameto & Kotler 1997), with physical impairments in the oropharyngeal or esophageal 
area (Fenton & Silverman 2004).  Due to discomfort with chewing and swallowing, patients 
can limit their intake resulting in weight loss (Fenton & Silverman 2004; USAID 2001).  For 
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example, some patients limit their food intake due to infection such as candidiasis, an 
infection caused by Candida yeast (USAIDS 2001).  
According to MacArthur & DuPont (2012) diarrhoea is a frequent symptom of HIV/AIDS, 
with up to 60% of PLWHA reporting to being affected.  In African adults, chronic diarrhoea 
has been used as a predictor of HIV-seropositivity (Wilcox, Wanke, Bartlett & Mitty 2013).  
In the HIV infected individuals, it remains a strong predictor of morbidity and mortality 
(MacArthur & DuPont 2012; Nel 2010).  Diarrhoea has a multitude of aetiologies with HIV 
itself being a potential cause.  The virus can infect the cells in the gastrointestinal tract and 
cause immune damage, especially to gut-associated lymphoid tissue [GALT] (Wilcox et al 
2003). Other potential causes of diarrhoea include: consuming contaminated food as a result 
of inadequate food and water hygiene; infectious pathogens; some drug therapies (Wilcox et 
al 2003); and bacteria and protozoa such as Cryptosporidium, Microsporidium, atypical 
Mycobacteria (Sharpstone & Gazzard Gazzard 1996).  
In South Africa, between 2005 and 2007, the Eastern Cape and KwaZulu Natal had the 
second lowest access to free potable water within a 200 meter radius (Barron, Day & 
Monticelli 2007).  This poor access to safe water might be one of the factors contributing to 
diarrhoea among certain parts of the South African population.  A decline in the incidence of 
infectious causes of diarrhoea has been noted in well resourced countries where HAART is 
freely available (Wilcox et al 2003).  Even so, HAART (particularly protease inhibitor 
ritonavir) itself has been associated with medication-induced diarrhoea which may damage 
the intestinal epithelial barrier (leaky-flux diarrhoea) and/or alter chloride ion secretion 
(MacArthur & DuPont 2012).  The interaction between diarrhoea and malnutrition is 
bidirectional, as diarrhoea leads to malnutrition while malnutrition exacerbates the increased 
risk of diarrhoea (MacArthur & DuPont 2012; Nel 2010; Wilcox et al 2003).  The detrimental 
effect of diarrhoea is mainly due to increased nutrient losses, malabsorption, and the 
inflammatory response (Nel 2010). WHO, FAO (2002) revealed that diarrhoea also leads to 
water and mineral loss from the body. It can accelerate disease progression through 
dehydration, weight loss, nutrient malabsorption, and severe malnutrition if left unattended 






Mason, Milovic, Lipman & Grover (2012) defined malabsorption as a condition of impaired 
nutrient absorption.  Malabsoption is a common phenomenon of HIV infection (Jiménez-
Expósito, Garcia-Lorda, Alonso-Villaverde, de Virgala, Sola, Masana, Arija, Izquierdo & 
Salas-Salvadó 1998), mainly due to usual episodes of diarrhoea experienced by patients 
infected with HIV/AIDS at some stage during the course of their illness (Fenton & Silverman 
2004).  HIV-related malabsorption has been associated nutritional deficiencies (Van der 
Hulst, von Meyenfeldt, van Kreel, Thunnissen, Brummer, Arends & Soeters 1998) and 
disease progression (Keating, Bjarnason, Somasundaram, Macpherson, Francis, Price, 
Sharpstone, Smithson, Menzies & Gazzard 1995).  According to Mason et al (2012), 
malabsorption happens as an outcome of a defect in normal nutrient absorption.  For example, 
defect in the luminal and brush border processing, or in the absorption into the intestinal 
mucosa or transport of nutrients into the circulation.  Numerous researches have shows that 
nutrient malabsorption plays a major role in HIV-associated weight loss and wasting, 
regardless of sufficient energy consumption (Macallan 1999; Jiménez-Expósito et al 1998; 
Gramlich & Mascioli 1995; Lakshmipathi & Jastremski 1989). 
Infection, either in the intestines or large bowel, can affect malabsorption of nutrients.  
Patients with intestinal infection of the small intestine have been recognized to suffer mostly 
from the malabsorption of carbohydrates, fats (Semba & Tang 1999; Jiménez-Expósito et al 
1998) proteins, minerals, water and vitamins (USAID 2001).   However, those with large 
bowel infections are allied with malabsorption of fluids and electrolytes (Fenton & Silverman 
2004).  The study conducted in San Francisco Hospital in United State of America found fat 
malabsorption (also known as steatorrhea) to be present in 50 percent of the sixty-one HIV-
infected adults with or without diarrhoea (Koch, Garcia-Shelton, Neal, Chan, Weaver & Cello 
1996).  Since fat is the most energy dense nutrient, its malabsorption is a potential causative 
factor in weight loss (Mason et al 2012).  Malabsorption of fat also reduces the absorption of 
the fat-soluble vitamins (vitamin A and E) which can compromise the immune system 
(USAID 2001; Semba & Tang 1999).  Moreover, signs of nutrient deficiencies can manifest 
in some patients (Mason et al 2012). Therefore, malabsorption clearly can contribute to HIV-
related malnutrition.   
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It is also worthwhile to mention that maldigestion is an established factor that interferes with 
nutrient absorption as it impairs the digestion of nutrients within the intestinal lumen or at the 
terminal digestive site of the brush border membrane of mucosal epithelial cell (Mason et al 
2012). 
 
2.7. Macronutrient requirements in HIV/AIDS infection 
2.7.1. Energy  
To maintain or achieve good health, an individual requires energy-providing nutrients. 
Macronutrients, namely carbohydrates, protein and fat are the main source of energy to the 
body.  HIV positive patients have a markedly increased resting energy expenditure [REE] 
(Hattingh 2005), even when they are on ART (Mabaso 2012).  According to Lakshmipathi & 
Jastremski (1989), inadequate macronutrient intake, malabsorption and metabolic 
disturbances in HIV are the underlying factors leading to increased REE which complicate the 
ability to meet energy requirement.  These disturbances result in either a hypermetabolic state 
with active infection (Castleman, Seumo-Fosso & Cogill 2004; Food and Nutrition technical 
Assistance programme [FANTA] 2004; WHO 2003), or a higher mechanical workload, such 
as the increased use of energy for breathing in patients with respiratory discomfort (Hattingh 
2005). 
 The WHO (2003) recommended that at the asymptomatic stage (WHO stage 1), energy 
requirements in PLWHA for maintaining body weight is 10% higher than that of healthy, 
uninfected individuals with the same energy variables, namely; age, gender and physical 
activity.  During the period of illness (WHO stage 2 and subsequently AIDS), energy 
requirements are further increased by 20% - 30% more than that of healthy, uninfected 
individuals of the same age, gender and physical activity level (WHO 2003) to compensate 
for elevated REE (Avert 2011; FANTA 2004). Opportunistic infections can potentially 
increase energy requirements by 50 - 100% (Fawzi, Msamanga, Spiegelman & Hunter 2005).  
Hattingh (2005) stated that even though REE has been proven to increase, energy 
expenditure, studies showed no increase in overall total energy expenditure (TEE).  Although 
the mechanism is not known, it is speculated that individuals compensate by reducing 





Diets that are adequate in protein may assist in improving a positive nitrogen balance and 
replenishing lean body mass (Onyango et al 2012). A suggested protein requirement of 1 to 
1.4 g/kg body weight and 1.5 to 2 g/kg body weight are for weight maintenance, and to 
replenish lean body mass (excluding individuals suffering from severe hepatic or renal 
disease) is recommended respectively (Fenton & Silverman 2004).  Malabsorption, common 
among PLWHA, has been proven to result in protein malnutrition and energy deficiency 
especially in underdeveloped countries (Lakshmipathi & Jastremski, 1989).  Protein-energy 
deficiency is associated with an impaired immune system and increase disease progression 
(Onyango et al 2012).  However, in spite of the above mentioned possible deficiency of 
protein among the HIV infected individuals, the WHO reported that there is insufficient 
evidence regarding protein requirements in HIV infected individuals.  Hence, the protein 
requirements of PLWHA are the same as that of healthy, uninfected individuals with the same 
requirement factors such as age, gender and physical activity level (Avert 2011).  The 
recommended protein intake is 12-15% of total energy (DoH 2007).  Hattingh (2005) 
conducted a study on macronutrient intake of HIV seropositive and seronegative women of a 
low socio-economic status living in Mangaung, Free State Province, South Africa.  The 
findings revealed that the median total protein intake of all women exceeded the dietary 
reference intake (DRI) of 46g/day.  However, the results of protein intakes from other studies 
vary widely, ranging from inadequate to intake above recommended dietary intake (RDI).  
There was no intentional increase in protein intake due to HIV infection recommended 
because of insufficient scientific evidence to support it (WHO 2003).    
2.7.3. Fats 
The recommended 30-35 % of total energy needs (appropriately 80g) should come from fats 
as there are no special requirements for HIV infection (DoH 2007).  The quality and type of 
dietary fat has been documented to either improve or suppress the immune function (Hattingh 
2005).  Antiretroviral (ARV) drugs may interact positively or negatively with foods that are 
high in fat (Pronsky et al 2001).  Some studies have reported on the beneficial role of dietary 
fat, such as increasing the bioavailability of non-nucleoside reverse transcriptase inhibitor 
(NNRTI) drugs (WHO 2003).  However, there is no data to suggest an increase in total 
dietary fat needs beyond normal requirements in HIV infected individuals (WHO 2003).  In a 
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local study determining the macronutrient intake of HIV positive women, total fat intakes 
exceeded the DRI of less than 30 % of total daily energy intake (Hattingh 2005).  This is not 
acceptable since excess intake of dietary fat has adverse effects on health.  Hence, total fat 
intakes in HIV patients should be maintained as 30-35% of total energy with the exception of 
diarrhoea associated with more advanced stages of HIV infection (WHO 2003).  Moreover, 
fat tolerance has also been suggested to vary amongst individuals (Fenton & Silvermann 
2004).  Thereby making special advice regarding fat intake for PLWHA is essential for better 
nutrient utilisation, metabolism, distribution or excretion and the effectiveness of specific 
drugs (Castleman et al 2004). 
 
2.8. Micronutrient requirement in HIV/AIDS infection 
According to Friis (2005), infection may lead to micronutrient deficiencies and micronutrient 
deficiencies may affect the risk of infectious disease morbidity.  The role of micronutrients 
(vitamins and minerals) in the maintenance and functioning of the immune system and 
improvement of infectious disease is well established (Cunningham-Rundles, McNeeley & 
Moon 2005).  However, the specific role of individual or/and multiple micronutrients in the 
prevention, care and treatment of HIV infection and related conditions merits further attention 
(WHO 2003).  According to Hattingh et al (2007) moderate to severe micronutrient 
deficiency is common among HIV positive individuals, especially women.  It has been 
documented that at the advanced stage of the HIV disease, deficiency of various vitamins 
dominate, leading to increased HIV progression, transmission and mortality (Kupka, 
Msamanga, Spiegelman, Morris, Mugusi, Hunter & Fawzi 2004).  Despite the evidence that 
micronutrient requirements are likely to be reduced when the HIV patient initiates ART, 
micronutrient deficiencies may persist and may affect absorption and efficacy of the drugs 
(Friis 2005).  Hence, HIV-infected people should consume diets that ensure micronutrient 
intakes at RDA levels (Castleman et al 2004; FANTA 2004).  There is a possibility that the 
diet may not be sufficient to correct nutritional deficiencies in HIV infected individuals, even 
during the intake of ART due to a decreased food intake, increased nutrient needs and 
gastrointestinal malabsorption (Drain, Kupka, Mugusi & Fawzi 2007).  Nutritional deficiency 
is noted especially in individuals from resource limited settings, as even before the infection 
set in, they consume an inadequate diet which fails to meet the nutritional requirements 
(FANTA 2004) and lack dietary diversification (DoH 2007).   
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Earlier studies from developed countries, before the use of ARV drugs, reported low serum 
levels of several micronutrient indicators such as vitamin A, carotenoids, vitamins B6, vitamin 
B12, vitamin C, vitamin E, folate, as well as selenium and zinc in adults (Friis 2005).   In a 
study conducted in the Free State to investigate micronutrient intake among HIV positive 
individuals, the intake of fat soluble vitamins, folate and vitamin C was less than 67% of the 
RDI/adequate intake.   In the same study, the intake of calcium, iron and selenium was also 
below 67% of the RDA (Hattingh et al 2007).  This finding was probably due to the high 
consumption of carbohydrates sources such as maize meal, which contains low levels of these 
nutrients.  Another study assessing nutrient intake and nutrient status of HIV seropositive 
individuals at Chulaimbo Sub-District Hospital, Kenya, the intake of vitamins and minerals 
was below the RDA (90%).  This was with the exception of iron and thiamine, because of a 
high intake of vegetables in the region (Onyango et al 2012).  In South Africa, the nutrient 
intake below RDAs can be expected because of low agrarian activities (HSCR 2005) and a 
lack of a dietary diversification (DoH 2007). 
 
Abrams, Duncan & Hertz-Picciotto (1993), investigated the impact of dietary intake on 
disease progression though determining the relationship between dietary intake at baseline 
and the development of AIDS over a six-year period in HIV seropositive homosexual men.  
Findings of this study showed that a high nutrient intake was associated with a significantly 
reduced risk of developing AIDS.  A reduced disease progression was statistically 
significantly associated with iron, vitamin E, riboflavin and the use of a multi-vitamin 
supplement.  The study conducted by Fawzi et al (2004) in Dar es Salaam, Tanzania, also 
found that multivitamins (vitamin B complex, C and E) impacted on slowing down disease 
progression in HIV positive patients.  Although serum selenium was also found to be low 
among HIV infected individuals (Friis 2005), however, there is inadequate evidence regarding 
the benefit of selenium supplements benefits (South African HIV Clinicians Society Expert 
Committee 2004).  Therefore more research is required to substantiate the above findings.  
Results from other studies raised concerns that some micronutrient supplements such as 
vitamin A and zinc can produce adverse outcomes in HIV-infected individuals, increase 
disease progression and decrease survival if used with no evidence of deficiency (Fawzi et al 
2004; Kupka & Fawzi 2002; Semba & Tang 1999).  
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According to FANTA (2004), optimal nutritional support for PLWHA play a critical role in 
survival of HIV infected individual (Castleman et al 2004).   Hattingh et al (2007) stated that 
early assessment and nutrition intervention are required to support HIV infected patients.  
Lategan et al (2010) suggested food supplements enriched with macro- and micronutrients to 
complement the diet are essential to improve the nutritional status of HIV and TB infected 
people.  However, there is insufficient published information on the effectiveness of food 
supplementation in HIV infected individuals.   
2.9. Malnutrition management strategies in South Africa 
Nutrition programmes have been in place in South Africa for a very long time.  These 
programmes include supplementation with food (such as beans and maize meal) and 
promotion of gardening (DoH 1999).  For several reasons, the programmes that have been 
implemented were not very effective in reducing malnutrition (DoH 1999).  Malnutrition 
remained a key priority issue which the new government undertook to address post the 
apartheid era (Steyn & Labadarios 2002).  The South African DoH developed a strategy 
aimed at solving nutrition problems in the country based on the recommendations of the 
Nutrition Committee which was appointed by the Minister of Health in 1994 (DoH 1999).  
The committee’s fundamental reason for formulation of the strategy, the integrated nutrition 
programme (INP), was to replace the fragmented and mostly food based approach of the past 
that was proven to be less effective to meet the long term development and health needs of its 
population (DoH 1999).  The INP strategy was formulated in 1995, and later became part of a 
broader integrated food security strategy [IFSS] (DoA 2002).  The INP strategy applied the 
UNICEF conceptual framework for determinants of malnutrition as a model to ensure optimal 
nutrition, prevention and alleviation of malnutrition in South Africa (DoH 1999).  There are 
eight focus areas of this strategy.  However, three aimed at eliminating malnutrition among 
adults in the general public. Namely: contributing to household food security; disease-specific 
nutrition support, treatment and counselling; and micronutrient malnutrition control (DoH 
2001).   
The INP strategy to improve household food security placed considerable emphasis on food 
based income generation projects allowing communities to solve their own nutrition problems 
(DoH 2001).  Due to constraints such as complex financial procedures, and lack of project 
management skills, the original intention of the INP to contribute to household food security 
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is still a challenge (DoH 2001).  Disease specific nutrition support, treatment and counseling 
strategies still encompasses nutrition and dietary practices for the prevention and 
rehabilitation of nutrition related diseases and illness (DoH 2001).  The Food and Nutrition 
Technical Assistance (FANTA) and World Food Program (WFP) (2007) reported that a 
disease specific nutrition support, treatment and counseling strategy incorporated into most 
national plans on comprehensive care and treatment of HIV, should be provided mainly 
through a clinical-model.  Hence, nutrition assessment, education and counselling are 
integrated into the routine clinic visits of HIV-positive adults aiming at providing capacity to 
overcome constraints to healthy eating.  Micronutrient malnutrition control addresses 
micronutrient deficiency in the population through a combination of strategies.  This includes 
supplementation (vitamin A and multivitamins), food fortification and iodization, promotion 
of dietary diversification and related public health measures (DoH 2001).   Food and nutrient 
supplementation, and therapeutic feeding are also provided to malnourished individuals, 
particularly those on anti-retroviral therapy (ART) as part of nutrition care and support 
(FANTA & WFP 2007; Anon 2003).  A reduction in the impact of opportunistic infections 
and symptoms such as oral thrush, diarrhoea and fatigue has been reported due to the 
provision of supplements at clinics (Oketch, Paterson, Maunder & Rollins 2011). While the 
importance of NCS strategies is well recognized, there is paucity of information regarding 
their impact on nutritional status. 
 
2.10. Ready-to-use supplementary foods to alleviate malnutrition in HIV infected 
individuals 
2.10.1 Background to the development of ready-to-use supplementary foods 
Management of malnutrition in inpatient and outpatient settings, has been changing 
over time with every new scientific discovery.  According to Briend (2001) in the WHO 
treatment protocol drawn up in 1999, the therapeutic milk WHO F100 was specifically 
developed for nutritional recovery of malnutrition in the nutritional rehabilitation of 
severe acute malnourished children.  This therapeutic milk was used for inpatient care 
in therapeutic nutrition centres with medical supervision and not distributed directly to 
families (WHO 2007).  There is evidence that therapeutic milk was successful in 
alleviating malnutrition and was effectively employed in hospitals (Scherbaum et al 
2009; Maleta, Kuittinen, Duggan, Briend, Manary, Wales, Kulmala & Ashorn 2004).  
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Despite these successes, challenges were encountered with the reconstitution of this 
product, as there was the need for close supervision during reconstitution.  This in turn 
increased demand for production capacity, as well as the need for access to clean safe 
water to minimize undesirable bacterial growth (Scherbaum et al 2009; WHO 2007; 
Briend 2001).  The product was also used for treating severely malnourished children as 
the vitamin and mineral content was too high to treat moderately malnourished child 
(Isanaka, Roederer, Djibo, Luquero, Nombela, Guerin & Grais 2010; Briend 2001).   
 
These above mentioned shortcomings led to the WHO amending the protocol for the 
management of severe malnutrition, encouraging the use of ready-to-use foods for 
inpatient and community-based management of undernutrition (Sunguya, Poudel, 
Mlunde, Otsuka, Yasuoka, Urassa, Mkop, Jimba 2012; WHO 2007).  Hence, there was 
a need for the development of ready-to-use therapeutic foods (RUTFs) with the 
intended use to improve the nutritional status of children as it has been proven to be 
acceptable to children (Briend 2001) and effective in alleviating malnutrition (Prudhon, 
Briend, Prinzo, Daelmons & Mason 2006). This product was used as a supplement to 
local diets and in managing moderate malnutrition (Briend 2001).  Examples of these 
ready to use therapeutic supplements include Plumpy-nut and Plumpy ‘doz produced by 
Nutriset in France (Manary 2005). From these RUTFs, ready-to-use supplementary 
foods “RUSFs” suitable for adults were also developed (Isanaka et al 2010).  
 
RUSFs are available in numerous forms such as compressed bars (de Pee & Bloem 
2009), biscuits and pastes (de Pee & Bloem 2009; Manary 2005).  RUSF reviewed in 
this dissertation is made up of peanut or soya paste, milk or whey powder protein, 
vegetable oil, sugar, minerals and vitamins, (Manary 2005; Maleta et al 2004).  The 
ingredients used in the production of RUSF are energy dense and/or high in nutrients 
(Manary 2005).  For several other reasons, the use of peanut based RUSFs is justified.  
It has low water activity which limits the risk of bacterial growth (Briend 1997).   Even 
when unrefrigerated for months, the supplement can still be safe for human 
consumption (GOTG 2010).  Since it requires no cooking, heat sensitive vitamins can 
be retained.  Moreover, this validates no need for labour, fuel and water and justifies its 
suitability for developing countries such as South Africa where some population are 
rural and has no access to water (Barron et al 2007).  In addition, the process of 
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producing this product is simple, uses basic technologies available in developing 
countries and is sustainable as the ingredients used in the manufacturing process is 
locally available (Diop, Dossou, Ndour, Briend & Wade 2003; Briend 2001).  RUSFs 
has been said to be practical to implement in resource poor settings because its 
production is less costly compared to the production of RUTFs (Isanaka et al 2010).   
Sibusiso® RUSF has been manufactured since 2004 from a Malawi produced groundnut 
by South African NGO, Gift of the Givers foundation.  It has been used to prevent 
malnutrition during illnesses and natural disasters (GOTG 2010).  Ingredients used in 
Sibusiso® also include soya milk extract, soya protein, oil (soya oil), sugar, vanilla 
flavouring and a vitamin and mineral premix (GOTG 2010).  Hence, this RUSF has 
been shown to be energy dense, as well as high in protein and micronutrients.   The use 
of soya improves the protein quality in a product as soya beans are known to have the 
highest protein content when compared to other cereals and legumes (Yeh, 
Resurreccion, Phillips & Hung 2002).  With macronutrient breakdown, a 100g of 
Sibusiso® RUSF provides approximately 2352 kJ/100 g of energy, with carbohydrates 
contributing 34% of total energy (48 g/100 g), protein and essential amino acids 
contributing 11% of total energy (16 g/100 g), and fats contributing 55% of total energy 
(35 g/100 g) (GOTG 2010).  Sibusiso® RUSF has been used by the South African 
Department of health as an effective nutrient supplement for individuals experiencing 
malnutrition, as is the case with TB, HIV and AIDS (Kindra, Coutsoudis & Esposito 
2011).    
2.10.2. Effect of ready-to-use supplementary foods 
RUSF has been shown to be efficacious in improving childhood malnutrition in studies 
conducted in several countries such as Tanzania, Chad, Ethiopia, Senegal and Malawi 
(Sunguya et al 2012; Isanaka et al 2010; Maleta et al 2004; Collins & Sadler 2002).  
Maharaj (2012) also conducted a study in a South African setting which aimed to 
investigate whether supplementation with a RUSF (Sibusiso®) could promote weight 
gain in underweight children between one and ten years of age living in Cato Manor and 
Chesterville in Durban, KwaZulu-Natal.  Underweight children who participated in the 
study were members of household food insecure families receiving food parcels 
supplied by the non-for-profit organisation Church Alliance for Social Transformation 
28 
 
(CAST).  Sibusiso® RUSF was successful in promoting weight gain among 
underweight children and was able to improve the overall wellbeing of children by 
alleviating the burden of disease and infection symptoms, while improving appetite, 
meal consumption and energy levels.   
Although there are numerous nutritional benefits to RUSF use observed in children on 
the African continent, evidence regarding its effectivity in adults is still lacking.  A 
randomized controlled clinical trial conducted in KwaZulu-Natal on the effect of 
Sibusiso® RUSF on breastfeeding HIV positive mothers on maternal and child health 
revealed no significant changes of the anthropometric status when comparing the trial 
and control group of mothers except for LBM.  This study also found that there were no 
significant differences in the incidence rate ratio (IRR) of opportunistic infections such 
as diarrhoea and candidiasis (Kindra et al 2011).   
When RUSF was used in adults, the product, Plumpy’nut®, was proven to enhance the 
nutritional status of HIV infected adults in Malawi, Uganda, Kenya and  Addis Ababa 
(see Table 2.1.below).  To date there has been a lack of similar studies conducted in 
South Africa on adults with a focus on nutritional status and disease improvement with 
RUSF.  Studies (Mabaso 2012; Mahlangu 2012) which have been conducted in South 
Africa regarding the acceptability of RUSF, substantiate the possibility of using RUSF 
to improve adult nutritional status.  Therefore, it posed beneficial to investigate the 
effectiveness of RUSF in a South African community setting by specifically targeting 














Table 2.1: Studies on the efficacy of ready-to-use supplementary foods in adults 
 
Study Location and 
population 







1600 patients on 
ART 
 
Adult HIV+ patients with 
moderate acute malnutrition 
(MAM) are provided with 
two sachets of RUSF 
(Plumpy’nut) daily until 
recovery from malnutrition 
or for a maximum of three 
months. Those with severe 
acute Mal-nutrition (SAM) 
are provided with four 
sachets daily until recovery 
or for a maximum of six 
months. 
62.2% of patients on ready to use food 
therapy were recovered reached BMI above 
18.5kg/m2.  Out of 77 (14.7%) who were 
severely malnourished (BMI less than 
16.0kg/m2) only 18 (23.4%) recovered.  Out 
of 127 (24.2%) who were moderately 
malnourished (BMI 16.00-16.99 kg/m2) 56 
(44.2%) recovered.  245 (79.4%) out of 320 
(61.1%) who were mild malnourished (BMI 
17.00-18.4 kg/m2) recovered. The therapy 
was most effective on people who were 
mildly malnourished.  
Ahoua et 
al  2011 




adults with BMI 
<17 kg/m2 and 
initiated on ART 
Patients received four 
sachets of RUSF (2000 kcal; 
Plumpy’nut ®, Nutriset, 
Malaunay, France) per day 
in the outpatient clinic, and 
were clinically assessed 
every two weeks or monthly. 
Duration: Patients stay no 
longer than 6 months on a 
programme. 
After receiving nutritional treatment for a 
median of four months, 524 (47.4%) of 
patients achieved an average weight gain of 
1.6 g/kg/day.  
149 (13.5%) discharged before reaching a 
normal BMI of 18.5kg/m2, 250 (22.6%) 
defaulted from nutritional program care, 132 
(11.9%) died, 26 (2.4%) transferred to 
another programme, and 25 (2.3%) stopped 







adults with BMI 
<18.5 kg/m2 
initiating ART. 
Experimental group: 245 
patients, 260 g/day (1,360 
kcal/day) of peanut-based 
Ready-to-use fortified 
spread (RUSF). 
Experimental group: 246 
patients, 374 g/day (1,360 
kcal/day) of corn-soya blend 
(CSB). 
Control group: none. 
Duration: 3.5 months 
After 3.5 months, Patients in the RUSF group 
achieved mean overall weight gain of 5.6 kg, 
with median BMI of 19.0 kg/m2.  Patients 
receiving RUSF, as compared to CSB, had a 
greater increase in BMI (2.2 ±1.9 vs. 1.7 ± 
1.6 kg/m2 [difference 0.5 kg/m2 95% CI (0.2 
- 0.8)] and fat free mass (2.9 ± 3.2 vs. 2.2 
±3.0 kg [difference 0.7 kg 95% CI [0.2 - 
1.2]).  
No significant difference in mortality, 
immune reconstitution, HIV suppression or 










2.11. HIV associated body fat distribution (lipodystrophy) 
 
2.11.1. Background on lipodystrophy  
Segatto, Freitas-Junior, Dos Santos, de Lima Ramos Pinto Alves, Barbosa, Filho & 
Monteiro (2012) stated that the introduction of highly active antiretroviral therapy 
(HAART) in the 1990’s as a standard therapy to treat HIV/AIDS, resulted in a 
significant increase in survival and quality of life of PLWHA.  These positive results are 
due to its action of fighting against infectious and opportunist diseases.  However, 
pharmacological control of the disease has the secondary adverse side effect of altering 
body fat distribution, characterized by morphological changes (known as lipodystrophy 
syndrome [LDS]).  Rossouw, Botes and Conradie (2013) explained the syndrome as 
being characterised by body habitus changes, most commonly a combination of 
lipoatrophy [loss of peripheral subcutaneous adipose tissue, usually in the face, limbs 
and buttocks] and lipohypertrophy [visceral adipose tissue accumulation, gynaecomastia 
and, in some cases, lipomatosis, especially in the dorsocervical area, known as a 
‘buffalo hump’].  Nevertheless, even patients who are not on HAART present with 
lipodistrophy (Rossouw, et al 2013). It is not clear whether HIV lipodystrophy is caused 
by the HAART or indirectly caused by fat that was lost in the periphery and deposited 
in the alternative visceral sites (Rossouw et al 2013).  
  
Metabolic changes include dyslipidemia, insulin resistance and lactic acidosis that are 
also common in PLWHA (Leach-Lemens 2009). These metabolic and morphological 
changes that are associated with excessive abdominal fat, increases the risk of early 
onset of cardiovascular disease (CVD), hypercholesterolemia, and diabetes mellitus 
(DM) in PLWHA (Domingo, Estrada, Lopez-Aldeguer, Villaroya, Martinez 2012; 
Segatto et al 2012).  Leach-Lemens (2009) clinical review affirm that the adverse 
impact of HIV LDS is more than just on physical health but also associated with 
psychological impact including poor body image, anxiety, depression, and low self 
esteem.  This clinical review further mentions that the body morphological change has 
been seen to be a new obvious HIV feature with the potential to disclose the status 
unintentionally.  Hence, there is foreseen decrease compliance to treatment and reduced 
effectiveness of the treatment due to stigma.   
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Overweight and obesity are common problems in PLWHA, especially women (Segatto 
et al 2012). They are also associated with high risk of developing HIV LDS, 
dislipidemia and insulin resistance (Segatto et al 2012).  This has raised a concern about 
the impact of RUSF if results show its potential for the significant improvement in 
weight. Therefore, HIV LDS should be routinely assessed, prevented and managed and 
more research should be done to identify potential causes and best management 
practices.  
 
2.11.2 Lipodystrophy assessment methods 
There are several methods used by researchers for assessing lipodystrophy due to lack 
of standardisation (Segatto et al 2012). These include self identification; assessment by 
physicians, anthropometric measurement, bioelectrical impedance analysis (BIA); 
computed tomography (CT) scan; magnetic resonance imaging (MRI); and dual energy 
X-ray absorptiometry (DEXA) (Segatto et al 2012; van Wyk 2009).  Objectivity, 
accuracy, cost and standardisation of classification of the above mentioned methods 
varies widely (van Wyk 2009).  Even though the best methods to assess lipodystrophy 
are those that give an exact image of body composition (MRI, CT scan and DEXA), 
they are not readily available in the clinical practice and they are too expensive (Segatto 
et al 2012).  According to van Wyk (2009), self identification has been suggested by 
several studies to be also accurate and more economical.  The method is simple relying 
on the responses of the participants.  Wanke, Barlett & Bloom (2013) reported that the 
other methods offer no additional benefit to patient self report and physical examination 
as they are difficult to interpret and norms are not available.  Some studies revealed that 
findings from the self reporting are matching to the results of the MRI scans showing 
that patients who self reported truncal enlargement had a significant excess visceral 
adipose tissue than those who reported no truncal enlargement (Engelson, Kotler, Tan, 
Agin, Wang & Pierson 1999).    
 
2.12. Summary  
PLWHA in resource-constrained settings such as sub-Saharan Africa are carrying a double 
burden of HIV and food insecurity and are therefore prone to nutritional deficiencies.  Apart 
from food shortages, HIV infection is also frequently associated with malnutrition due to 
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causes such as lack of appetite, increased nutrient requirements due to increased metabolism; 
and decreased absorption due to opportunistic infections.   Besides this, the REE in HIV 
infected individuals has been shown to be higher than that in their HIV uninfected 
counterpart.   Hence, effective supplementary programmes are needed in order to decrease the 
incidences of malnutrition in PLWHA by providing adequate levels of energy and nutrients.  
 RUSF was initially designed to replace WHO F100 due to its shortcomings in the 
management of malnutrition.  This was largely due to the fact that the ingredients used in the 
manufacturing of RUSF are energy dense and high in nutrients.  RUSF are convenient and 
safe as they require no additional preparation, no addition of water and can be used safely in 
rural settings without the risk of bacterial contamination.  RUSF are adaptable and sustainable 
as the ingredients and technology used to manufacture these spreads are simple.  Locally 
produced RUSF have been found as effective as imported RUSF thereby reducing the cost of 
these supplements.  The studies reviewed indicated positive outcomes of RUSF in prevention 
of malnutrition in children. However further studies are needed to investigate the 
effectiveness of RUSF such as Sibusiso® RUSF on HIV positive individuals, especially in the 
South African community setting.   
Patients who are on HAART sometimes present with LDS, but even those who are not on 
HAART can still present with lipodystrophy.  The cause of it is not clear, therefore, more 
research should be done to identify the potential causes.  LDS is associated with excessive 
abdominal fat which increase the risk of CVD, hypercholesterolemia and DM.  Hence, 
lipodystrophy should be routinely assessed, prevented and managed.  There are several 
methods for assessing lipodystrophy syndrome.  The studies reviewed indicated the subjective 
self reporting method as a reliable and more economical method in assessing lipodystrophy 












This chapter provides a detailed explanation of the different methods used in addressing the 
research problem. The study design, study population and sample selection, methods and 
materials used in collecting and analysing the data are fully described. 
 
3.1 Research design 
 
The main purpose of this study was to determine the effect of a peanut based ready-to-use 
nutritional supplement [Sibusiso®], on HIV positive adults on antiretroviral therapy, 
attending the 1000 hills community helpers’ centre, Durban, KwaZulu-Natal.  The effect of 
this intervention was to be determined through identifying whether there was an improvement 
in BMI.  The study aimed to determine whether there was an improvement in predominant 
disease conditions and symptoms experienced by HIV infected individuals.  Furthermore, it 
determined if there was a general improvement of appetite, meal consumption and energy 
levels using a self reported method.  Lastly, the study seeked to identify if there were any 
changes in body fat distribution in adults on ART after being supplemented with Sibusiso® 
RUSF.  This research is a descriptive study whereby data was collected using a cross-
sectional method.  It includes 50 participants between the age of 20 and 78 years.  
According to the Medical Research Council [MRC] (2010), in many circumstances, 
randomised controlled trials are the method of choice for evaluating interventions because 
randomisation, coupled with design features such as blinding provide the most robust ways of 
minimising biases. However, in the current study randomisation was difficult for practical 
reasons.  It would have been unethical to randomly select a few at risk participants to receive 
Sibusiso® RUSF, taking into account that almost all of the HIV clients attending the centre 
have one or more factors that have been anecdotally suggested to improve with RUSF intake.  
In addition, this was an intention-to-treat study; therefore a control group was not included in 






3.2. Study population and sample selection 
 
At the time of data collection, there were approximately 100 adults (over 18 years) attending 
the 1000 hills community helper’s centre which provide ART to HIV infected participants. 
No sampling was done as all adults who were on ART were eligible for RUSF as part of 
clinical assistance sponsored by the Gift of the Givers.  All participants were monitored at 
each visit.  However, for the purpose of this study, the data for only those who met the 
inclusion criteria was used for analysis.   
Hence the inclusion criteria for the study were; 
 Being HIV positive 
 Receiving ART from 1000 hills community helpers’ centre 
 Not pregnant 
 Must attend at least four consecutive visits 
 Be 18 years  of age or older 
 Not taking other supplements intended for enhancing weight gain. 
 
Of the 100 adults receiving RUSF 50 were eliminated from participation in the study because 
they could not attend the community helper’s centre for four consecutive visits due to reasons 
that included defaulting on treatment, migrating, and changing the site of collecting their 
medication.  This resulted in a final number of 50 participants eligible for statistical analysis.  
We defined ART-treated HIV positive patients as those who’s sero-status was confirmed to 
be positive using standard laboratory methods and taking ART according to the national 
guidelines of South Africa.  The 50 adults included in the study still represented a sample of 
adults on ART attending the 1000 hills community helpers’ centre. 
 
3.3 Study methods and materials  
 
The supplement was a peanut/soya milk spread enriched with 6 micronutrients and came 
packaged in plastic tubs.  At each visit the participant was given 3 tubs of Sibusiso® ready-to-
use supplementary food as a monthly supply.  Participants were instructed to take a daily 
serving of 4-6 heaped teaspoons of the nutrition supplement.  Trained professional nurses 
from the centre were responsible for collecting data at each visit with the researcher present 
on some days for monitoring the process.  Intensive training of the centre nurses on 
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interviewing technique and taking anthropometric measurements for the purpose of 
standardizing the procedure was done by the consulting dieticians of the Sibusiso® Product 
(Pty) Ltd. The researcher assisted with ongoing monitoring of the data collection process.  
The nurses who served as field-workers were fluent and literate in English and isiZulu, and 
had experience in nutritional monitoring of HIV infected adults.  The monitoring tool used in 
this study was an amended one used in a similar local study on children (Maharaj 2012).  
Although the monitoring tool was originally designed to be used in severely malnourished 
children under the age of five years, it was adapted to be able to facilitate the collection of 
insightful and relevant information to answer the research question.  
 
Data collection days were strategically planned on the same day that ART was collected in 
order to ensure a high attendance rate and convenience to participants.  On the first visit, 
information on the socio-environmental conditions of the subject was captured.  This included 
employment, and availability of water, electricity, indoor flushing toilets and a fridge.  The 
baseline information also assessed the frequency (daily, weekly or monthly) of consumption 
of different food groups.  All baseline information aimed at identifying the risk of 
malnutrition in participants that were included in the study.   Thereafter, on a monthly basis 
data on anthropometrics (BMI), symptoms, appetite changes, and disease conditions was 
recorded on the monitoring tool (see Appendix B).  Towards the end of the study the 
researcher conducted an interview with each participant to assess the body fat distribution of 
participants after using the supplement using a self reporting method (see Appendix C). 
 
Variables included in the study  
3.3.1. Anthropometric measurements 
Anthropometric measurements included weight and height of participants.  All measurements 
were repeated twice as per ISAK (International Society for the Advancement of 
Kinanthropometry) to two decimal places by a researcher or a research assistant to enhance 
reliability but only a mean value was recorded.  If the two measurements differed 
significantly, the third reading was measured and the median used.  BMI was calculated by 






 Weight gain or loss  
The weight (kg) of the participants was measured on each day of supplement collection.  
Any change in weight was documented, and indicated as an increase or decrease in 
weight from the previous weight recorded. 
 
Procedure of weight measurement 
The following method was used: 
 The electronic scale was recalibrated before each measure 
 The electronic scale was placed on an even surface in the clinic 
 The electronic scale was turned on and the nurse waited until it read 0.00 kg 
 The participant was asked to remove shoes, socks and any other clothes or 
object that that could contribute to extra weight.  Hence they were weighed 
wearing light indoor clothing 
 The participant was asked to stand in the middle of the scale with their weight 
evenly distributed on both feet and with hands on their sides. 
 The weight was recorded in kilograms into 2 decimals 
 The weight was measured twice and the average was recorded. The third 
reading was measured if the first two readings differed significantly, and median 
recorded. 
 
 Height  
The height (m) of participants was measured using a stadiometer at baseline.  
 
Procedure of height measurement 
 The stadiometer was placed on a level surface 
 The participant was asked to remove shoes, socks and hair, if tied up, was 
untied 
 The participant was asked to stand with heels together, arms to the side, legs 
straight, shoulders relaxed, head in a Frankfort horizontal plane and buttocks and 
shoulders touching the stadiometer 
 Just before the measurement was taken the subject was asked to take a deep 
breath and hold it while maintaining an erect posture 
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 The sliding headpiece was then lowered upon the highest point of the head 
with adequate pressure to compress the hair 
 The sliding headpiece was then locked in place and the reading was taken 
 The height measurements were read into 2 decimal places in metres and two 
readings were taken, an average was then recorded.  The third reading was done if 
the first two measurements varied significantly and a median recorded. 
3.3.2  Diseases symptoms  
 Participants were interviewed if they presented with symptoms as per the 
monitoring tool. Symptoms included nausea, diarrhoea, fever or vomiting. 
Participants had to respond either yes or no to these questions.  It was important to 
identify if the participants had experienced any of these symptoms since it could 
affect food intake or absorption of nutrients and ultimately weight gain.  
3.3.3 Disease conditions 
 Gastroenteritis: A subject was identified by the research assistant as having 
gastroenteritis, if they presented with symptoms regarding loss of appetite, 
nausea, vomiting and diarrhoea.  
 Diarrhoea: A working definition of diarrhoea used was the abnormal passage of 
≥3 unformed stools per day or a liquid stool (MacArthur & DuPont 2012). 
 Diarrhoea (past 2 weeks):  The duration of diarrhoea was also considered to 
determine whether acute or chronic.  Diarrhoea with a duration of 2 weeks was 
considered as chronic. 
 Dehydrated: A subject was identified as being dehydrated if they presented with 
symptoms such as extreme thirst, dry lips and tongue, an increase in heart rate and 
breathing rate, dizziness, confusion and lethargy or mucous membranes.  
 Mouth sores: The researcher/research assistant assessed participants for mouth 
sores by inspecting the mouth.  
 Oral thrush: The researcher/research assistant assessed oral thrush by inspecting 
the mouth of participants for fungal (candidia) infection that present itself as 
creamy white lesion with cottage cheese appearance on the tongue, roof of mouth, 
gums and tonsils (Peters 2007). 
 ART: Each subject was asked if he/she has initiated ART, and this was confirmed 
by checking their clinic card.  
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 TB: Each subject was asked if he/she had been tested for TB and was confirmed 
by the Directly Observed Treatment Short-course (DOTS) card. Test results were 
noted on the monitoring tool. 
3.3.4  Appetite  
 Participants were questioned about their appetite. Appetite was rated as either 
being poor or good. For the purpose of this study, good appetite was defined as 
always having a natural desire to enjoy your food at meal times.  Poor appetite 
was defined as frequently having no desire to eat at meal times. 
3.3.5  Meal consumption  
 Meal consumption was measured by asking subject how much food they were 
consuming on average at each meal. Using a standard bowl (about 500ml) as a 
reference, patients were asked to rate the amount of food consumed as ¼, ½ or a 
full bowl of food.  
3.3.6  Energy levels  
 Participants were asked to rate their level of energy at each visit. Energy levels 
were classified as being very weak, weak, fine or full of energy.  For the purpose 
of this study, the following definitions were used: 
Very weak: - being fully dependent of assistance for normal duties such as to 
walk, cook, clean the house due to a lack of strength. 
Weak: - not having adequate strength to perform normal household physical 
duties, partially depend on assistance. 
Fine/fair: - having a fair strength to perform normal physical household duties 
Full of energy: - being able to perform strenuous physical duties without a 
struggle. 
3.3.7  Other supplements  
On the first day that participants received a supplement, they were asked whether 
they were receiving a multivitamin, or any therapeutic porridge. This was done in 
order to eliminate them from taking supplements with a potential of influencing 
nutritional status.  Therefore, ensuring that the study findings are a true reflection 
of the impact of the RUSF supplementation.  
3.3.8       Body morphological changes 
Morphological change assessment was done using a subjective self reporting 
method.  Morphological change assessment was defined as an accumulation or 
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wasting of fat in certain body areas including neck, breast, abdomen, face, arms 
and buttocks.  Lipohypertrophy referred to a generalized fat gain in the specific 
area, while lipoatrophy referred to a generalized fat wasting in specific areas.  The 
severity was scored and recorded as mild (slightly noticeable), moderate (readily 
obvious), or severe (obvious).  Cases with morphological changes were defined as 
participants with one or more moderate and/or severe features of lipohypertrophy 
and/or lipoatrophy (see Appendix C). 
 
3.4.  Ethical Considerations 
Ethical approval for the study was obtained from the Human and Social Ethics Committee, 
University of KwaZulu-Natal, Reference Number HS/0373/011M. All participants were 
requested to sign a written consent form before participating in the study. The study was 
explained to them in their home language and it made clear that they can withdraw at any 
point in time. 
3.5 Data analysis 
Statistical data analysis of the variables are discussed in this section.  Data was entered into a 
Microsoft database (©MS Excel 2010). It was rechecked for any missing information and 
entry errors. A unique subject identification number was used to maintain confidentiality.  
Data was transferred to and analysed using SPSS (Statistical Package for Social Science), 
version 18.0 (SPSS Inc., Chicago, III, USA) which is a statistical analysis computer program. 
Statistical significance was set at a P-value of less than or equal to 0.05. 
Sub-problem one: To determine a change in BMI of HIV positive adults on ART 
supplemented with Sibusiso® RUSF. 
Anthropometric measurements between subsequent visits for each patient was analysed using 
the software, SPSS (Statistical Software for Social Sciences) version 18.  Basic descriptive 
statistics (means ± standard deviations) were used to describe the characteristics of 
participants at each visit.  Comparisons were made between mean BMI in visit 1 (before any 
supplementation was given), and subsequent visits.  A paired t-test was used to measure 
differences in BMI between subsequent visits.  Pearson correlation was used to identify 
relationship between BMI changes and other factors that could possible contribute to this 
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change, such as availability of vegetable gardens.  A p-value of less than or equal to 0.05 was 
considered significant.   
Sub-problem two: To determine the most prevalent symptoms and disease condition of 
patients on ART. 
At each supplementation day, data was collected regarding the disease symptoms which were 
being experienced by participants.  Symptoms included nausea, diarrhoea, fever and 
vomiting.  Disease conditions were diarrhoea (past 2 weeks), dehydration, mouth sores, oral 
thrush, gastroenteritis, TB and HIV.  The frequencies of these symptoms or conditions were 
calculated by adding the number of diseases and symptoms that participants presented with on 
each data collection day.  The disease condition that the participants presented with 
throughout the period of data collection was identified as being the predominant disease 
condition experienced among participants. 
Sub-problem three: To determine whether symptoms and disease condition of patients 
improved after supplementation. 
Cross tabulations and chi square t-test were used to compare the symptoms from the first visit 
to the last participant visit.  
Sub-problem four: To determine whether appetite, meal consumption and energy levels 
improved among ART patients after supplementation with Sibusiso® RUSF and possible 
contributing factors. 
On each supplementation day, data was collected regarding level of appetite, meal 
consumption levels and energy levels of participants observed in the past month.  At the end 
of the three month supplementation period, data collected was analysed to identify whether 
there was any overall improvement in appetite, meal consumption and energy levels. To 
determine improvement in appetite and energy levels, cross tabulations and chi square t-test 
were used to compare the appetite and energy levels from the first visit to the last patient visit.  
Pearson correlations were conducted to determine contributing factors to appetite and energy 
level. 
Sub-problem five: To determine change in body fat distribution of adults after being 
supplemented with Sibusiso® RUSF. 
Morphological change assessment was done using a subjective self report method at the end 
of three months of supplementary period.  Cases were defined as participants with one or 
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more moderate and/or severe features of lipohypertrophy and/or lipoatrophy.  Data was 
analysed by adding the number of confirmed cases after the end of assessment period.  
Pearson correlation was used to determine relationship between BMI change and lipoatrophy 
or lipohypertrophy. 
 
3.6   Summary 
 
In this non randomised intervention, 50 HIV positive adults on antiretroviral therapy, 
attending the 1000 hills community helpers’ centre, Durban, KwaZulu-Natal participated in 
the study.  A monitoring tool was used to obtain data and anthropometric measurements of the 
supplemented participants at each of the four consecutive visits by a researcher and/or the 
trained nurse (research assistant) at the research site.  Data was then analysed to determine the 
effect of the intervention by identifying whether there was an improvement in participant 
BMI. The improvement in predominant disease conditions and symptoms experienced by 
HIV infected participants was also investigated.  Data analysis also showed whether there was 
any general improvement in appetite, meal consumption and energy levels.  Lastly, the study 
seeked to identify if there were any changes in body fat distribution on adults on ART after 





















Chapter four presents the results of the study according to the sub problems outlined in 
chapter one. 
 
4.1. Sample characteristics 
 
A total of 50 adults on ART were supplemented for a period of three months with Sibusiso® 
RUSF.  No control group was used in this study.  Table 4.1 depicts sample characteristics if 
the participants. The average age of the participants was 40 years.  Majority of participants (n 
= 32) were over the ages of 35 years.  The study consisted of 88% (n = 88%) females and 
12% (n = 6) males.  All participants were of an African origin.  Average weight of 
participants was 60.02 kilograms and the average height 1.63 metres.  
Table 4.1:  Sample characteristics of study participants. 
Variables  N (%)* Variables  N (%)* 
Age  Race  
18-25 05 (10) African 50 (100) 
26-35 13 (26)  
36-45 16 (32) Health status 
46 and above 16 (32) HIV/TB 07 (14) 
Average age ( 40 years) HIV 43 (86) 
Gender Average weight (60.06kg) 
Male  06 (12) Average height  (1.63m) 
Female  44 (88)  
 
TOTAL 50 (100) 
                     * % of total sample (n = 50) 
 
Figure 4.1 illustrates the background of participants by showing the resources that they have 
access to at home.  Seventy-four percent (n=37) of participants had access to a stove, 68% 
(n=34) had access to running water, 16% (n=8) had access to indoor flushing toilets, 54% 
(n=27) had access to a fridge and 78% (n=39) had access to electricity.  Of the 50 participants 





            Figure 4.1:  Resources available to participants with a potential to influence   
nutritional status. 
Figure 4.2 illistrates the frequency of foods consumed at by participants at baseline 
assessment. Water, bread/potatoes/phutu and porridge were consumed on a daily basis. Eggs, 














4.2. Nutritional and health effects of Sibusiso® RUSF on HIV positive adults receiving 
ART 
4.2.1 To determine whether the BMI of HIV positive adults on ART supplemented with 
Sibusiso® RUSF improved after a three months supplementation period. 
The mean BMI values from visit one (baseline) to visit four were compared to the initial BMI.  
This was done to determine how the supplement has impacted on the BMI of participants in 
the course of the study.  Table 4.2.below shows the results. 
Table 4.2: The average BMI values from visit one to visit four at clinic 









P-level (two-tailed) of <0.05  considered to be significant 
 
There was a gradual increase in the mean BMI of participants from the first to the last date of 
supplementation. Based on the paired-sample-t-test, comparing visit 1 and visit 2, a 
significant increase in BMI was noted (p<0.05). Between visit 2 and visit 3, a non-significant 
increase in BMI was noted (p>0.05).  A non-significant increase in BMI was also noted from 
visit 3 to 4 (p>0.05).   However, when comparing the initial BMI of the participants to their 
final BMI, a significant improvement was noted (p< 0.05).  Twelve percent of participants at 





.  There was no significant correlation between the baseline BMI and 
BMI changes. Yet, there was a weak positive correlation between baseline weight and having 
a vegetable garden (r
2
=0.409; p=0.004).  However, there was no correlation between having a 
vegetable garden and vegetable consumption (r
2
=0.001; p=0.994).  Instead, a weak positive 
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correlation was measured between the change in BMI between the baseline to end of 
supplementation and having access to running water (r
2
=0.379; p=0.009). 
4.2.2. To determine whether predominant symptoms experienced by adults on ART improved 
after supplementation with Sibusiso® RUSF. 
The symptom with the highest prevalence at the start of supplementation was fever, followed 
by nausea and diarrhoea (past 2 weeks).  However, even though by the fourth visit most 
symptoms were still present, the frequency of nausea had declined.  Participants also reported 
to experience significantly fewer episodes of fever between the first and the last visit [χ2 (1, 
n=47) =3.993; p<0.005].  As depicted in Figure 4.3, from visit 1 to visit 4, participants 
reported a steady but significant decline in vomiting [χ2 (1, n=47) =11.937; p=0.001].  There 
was also a significant improvement in the presence of gastroenteritis [χ2 (1, n=45) =6.648; 
p=0.05].  There was however, no change/ improvement reported in episodes of diarrhoea two 
weeks prior to the clinic visit when comparing the first and the last visit.  There was a non-
significant improvement in nausea after a three months supplementation.  A non-significant 
increase in prevalence of symptoms was observed in the second visit among participants. 
 
Figure 4.3: Most prevalent disease symptoms experienced by the participants at baseline, 
and changes in episodes throughout the supplementation period. 
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4.2.3. To determine whether appetite, meal consumption and energy levels improved among 
adults on ART supplemented with Sibusiso® RUSF 
An improvement in appetite was observed among participants from visit 1 to visit 4 (Figure 
4.4).  When observing the trend in appetite a general improvement was noted during the 
supplementation period.   
               
Figure 4.4: Appetite level of participants during supplementation period 
There was weak positive correlation between appetite levels and meal consumption measured 
from the baseline to the second visit, and a moderate positive correlation between appetite 
levels and meal consumption measured in the second to the last forth visit.  There was also a 
weak to moderate positive correlation between appetite levels and also improved energy 








    Table 4.3: Correlation between appetite levels and other variables 











baseline 0.366** 0.010 
2 2 0.643** 0.000 
3 3 0.647** 0.000 




baseline 0.094** 0.522 
2 2 0.397** 0.006 
3 3 0.405** 0.007 
4 4 0.526** 0.000 
R
2
: Pearson Correlation coefficient; ** Pearson’s correlation is significant at the 0.01 
level (2-tailed) * Pearson’s correlation is significant at the 0.05 level (2-tailed) 
 
There was a general improvement in meal consumption by the participants (Figure 4.5).  In 
the first visit (at baseline) 60% (n=30) of the participants reported to consume a 1/4 bowl of 
food at most meals.  However, by the fourth visit, only 18 % (n=9) of participants reported to 
consume a 1/4bowl of food.  Twenty-four percent (n=12) of participants reported to consume 
a ½ bowl at baseline assessment, this number dropped to 10% (n=5) after a month of 
supplementation in the second visit.  The number of participants consuming a ½ bowl then 
started to rise again the third visit to 20% (n=10) and then reached 26% (n=13) by the forth 
visit.   The number of participants consuming a full bowl of food had increased from 14% 
(n=7) in the first visit (at baseline) to 52% (n=26) in the third visit and decreased slightly to 
46% (n=23) in the last visit.  Overall, from the first to the last visit, there was a two third 





       Figure 4.5: Meal consumption by the participants  
From Figure 4.6 it can be seen that there was a general improvement in energy levels of the 
study participants.  Only 2% (n=1) of the participants rated themselves as being very weak in 
the last visit, which was a sharp decrease from the 28% (n=14) in the first visit.   Twenty four 
percent (n=12) of the participants reported to have a weak amount of energy by the end of the 
study, representing a decrease from 70% in the first visit.  Fifty four percent (n=27) reported a 
fair amount energy by the end of the fourth visit. 
 
         Figure 4.6: Energy levels of participants during the course of supplementation 
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There was a weak negative colerration between energy level and reported cases of 
gastroenteritis.  This was reported for baseline, visit two and at the last visit.  There was  no 
correlation in visit 3, and is depicted in table 4.4.   There was a weak negative correlation 
beween energy level and reported cases of fever in the second and third visit.  However there 
was no correlation identified between energy level and fever episodes at baseline and on the 
last visit.  There was no correlation between energy level and reported cases of persistant 
diarrhoes (more than two weeks) at baseline and in the second visit.  However, a weak 
negative correlation was measured in the third and the forth visit.   
 
    Table 4.4: Correlations between energy levels and gastroenteritis,fever, and diarrhoea 
(previous two weeks) 











 (Baseline)  
Gastroenteritis 
 (Baseline) -0.326* 0.025 
2 2 -0.428** 0.003 
3 3 -0.289 0.054 
4 4 -0.407** 0.005 
(baseline)  
Fever  
(Baseline) -0.146 0.318 
2 2 -0.308* 0.033 
3 3 -0.489** 0.001 




Baseline -0.191 0.189 
2 2 -0.285 0.055 
3 3 -0.329* 0.027 
4 4 -0.422** 0.003 
R
2
: Pearson Correlation coefficient; ** Pearson’s correlation is significant at the 0.01 level 
(2-tailed) * Pearson’s correlation is significant at the 0.05 level (2-tailed) 
 
4.2.4 To determine if there was any observed changes in body fat distribution on adults on 
ART after being supplemented with Sibusiso® RUSF. 
A group of 20 study participants participated in assessment of morphological changes during 
the supplementary period (Table 4.5). Of the 20 participants, 20% participants had 
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lipodystrophy.  Ten percent of the positive cases experienced moderate lipohypertrophy,  5% 
in the breast and the other 5% in the waist.  The other 10% liposystrophy positive cases 
reported having severe lipohypertrophy both in the waist and abdominal area.  Few cases of 
mild lipohypertrophy were reported, mainly in the breast and waist; and mild lipoatrophy was 
reported for numerous body part.  However, mild lipohypertrophy/lipoatrophy was not 
counted as cases of lipodystrophic syndrome.  There was no correlation between BMI change 
and lipoatrophy or lipohypertrophy. 
Table 4.5: Distribution of body fats in the participants over the three months period 
 Lipohypertrophy Lipoatrophy 
Neck Breast Waist Face Arms Buttocks Legs 
Mild 10% 20% 15% 5% 10% 10% 10% 
Moderate  5% 5%     






 RUSF was able to gradually promote weight gain among HIV positive participants 
supplemented for a period of three months.  The most predominant symptoms experienced 
before supplementation was fever followed by nausea.  Persistent diarrhoea was the most 
predominant disease condition reported by participants at baseline.  Appetite and meal 
consumption increased during the three months supplementation period.   The energy levels 
among supplementation participants were found to increase during the period of 
supplementation, with the majority of participants reported to have fair to full energy levels 
on the last visit.  Out of twenty HIV positive participants 20% reported moderate 











The main purpose of this study was to assess the effect of Sibusiso® RUSF on HIV positive 
adults on ART, attending the 1000 hills community helpers’ centre, Durban, KwaZulu-Natal.  
In Chapter 4, results were reported for changes in BMI; predominant disease conditions and 
symptoms; change in appetite, meal consumption and energy levels; and also body fat 
distribution for adults on ART after being supplemented with Sibusiso® RUSF.  The results 
will be discussed in this chapter, with special emphasis on the study objectives and reflection 
on past research within the context of each of these.  
5.1.   Significant findings in relation to the study objectives 
5.1.1 BMI of HIV positive adults on ART supplemented with Sibusiso® RUSF was improved 
after a three months supplementation period. 
Weight management is crucial in an individual living with HIV (DoH 2007).  However a 
change in weight in HIV is multifactorial in its aetiology (South African HIV Clinicians 
Society Expert Committee 2004).  The mean BMI values from visit one to visit four was 
compared to determine how Sibusiso® RUSF has impacted on the BMI of participants.  
Results showed that there was a gradual increase in BMI in the course of supplementation.  
This was sustained throughout the study.  The RUSF in this study has therefore, promoted 
weight gain among HIV adult participants aged 20 to 78 years.  These findings are similar to 
the findings from studies conducted by Ahoua et al (2011) and the study by Ndekha et al 
(2009), who both demonstrated that RUSF improved weight gain in adult participants.  
Several other studies documented similar findings (Sunguya et al 2012; Maharaj 2012; 
Isanaka 2010; Maleta et al 2004; Collins & Sandler 2002; Bried et al 1999), even though they 
were conducted on children.  These results are in contrast to a study conducted on HIV 
positive mothers in KZN where RUSF had no impact on nutritional status (Kindra, 
Coutsoudis & Espisito 2011).  Yet, it is not suggested that the results should be interpreted as 
controversial. Many factors should be taken into consideration here (such as poor acceptance 




In addition, the increase in mean BMI could have been due to the high energy content of 
Sibusiso® RUSF, which is approximately 2352 kJ/100g.  This is supported by the scientific 
backing that increased energy intake is the main contributor to weight gain, particularly 
sourced from dietary fat.  RUSF provide additional energy the local diet (Isanaka et al 2010).  
Keeping in mind the average age of participants (40 years) and the daily recommended dose 
of Sibusiso® RUSF (4-6 heaped teaspoons), it can be reasoned that the energy provided by 
the RUSF only, falls well below the RDA.  However, the additional energy and nutrients 
improves dietary intake, hence participants are more prone to meeting the RDAs as was 
pointed out by Maleta et al (2004).  Besides, Maleta et al (2004) reported that the 
micronutrients in RUSF improve micronutrient status, which in turn improves appetite.  
Furthermore, improved appetite improves food intake which promotes weight gain.   It is 
highly likely that in the current study, patients gained weight via the same mechanism.  However, 
this will be discussed in more detail later on in this chapter.   
As previously mentioned, Sibusiso® RUSF has been reported to be highly acceptable in HIV 
infected patients (Mahlangu 2012; Mabaso 2012).  It is speculated that this could have 
improved adherence to the supplementation programme.  Yet, there was no measure of 
acceptance in our study, even though none of the volunteers complained about the product.   
However, this is in contrast to the findings from the study conducted by Kindra et al (2011) 
who reported poor adherence to RUSF with mothers not consuming the daily amount of 
supplement according to protocol.  There were even occasional days when they did not use 
the supplement.  In this study, participants reported the unacceptable sweet taste of the 
product to affect their compliance. It can therefore be assumed that a positive weight gain 
suggests that in the current study, there was a better acceptability and adherence to the 
treatment by the study participants. 
No significant association was found between the starting weight (at baseline) and changes in 
BMI (r
2
=0.003; p=0.982).  In some instances, studies have shown that the response to 
treatment, in HIV infected individuals starting ART, to some extent, depend on the baseline 
nutritional status of the individual (Ciliberto, Sandige, Ndekha, Ashorn, Briend, Ciliberto, 
Manary 2005).  The findings of our study show that the RUSF can be used in patients at 
different stages of disease progression, regardless of their BMI.   
It cannot be overlooked that twelve percent (n=6) of the participants did not manage to 
achieve a normal BMI (18.5-24.9kg/m
2
) at the end of the intervention period.  A weak 
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positive correlation between the changes in BMI and running water (r
2
=0.379; p=0.009) was 
measured.  Poor access to water (68%, n=34) was noted in the community, in general.  The 
above mentioned finding substantiate that the success of RUSF in improving BMI can be 
determined by external factors, such as those outlined in the UNICEF conceptual framework 
(DoH 1999).  Also, it is suspected that the persistent diarrhoea that dominated in this study, 
could have for instance contributed to poor weight gain.  A small portion (18%) of 
participants reported a low food intake on the last visit, even though their overall food 
consumption improved.  It is expected that an improved food intake would have a beneficial 
impact on weight gain, which in this study, was the case.   
5.1.2. Predominant symptoms experienced by adults on ART improved after supplementation 
with Sibusiso® RUSF. 
Nutrition and immunity have a synergistic relationship and deficiencies in either can have 
serious health implications (Lategan et al 2010).  Inadequate diet which fails to meet the 
nutritional requirements can cause nutrient deficiencies and compromise the immunity in HIV 
positive people.  The results from a current study showed a lack of dietary diversity, 
characterised by high intake of carbohydrates rich foods with low levels of other nutrients and 
less frequent consumption of other foods (Figure 4.2).  It is therefore also important to 
acknowledge that the improvement in disease symptoms documented in this study, is 
independent of dietary practices.  Apart from lack of dietary diversity, food shortages (FAO 
2008) and increased nutrient requirements due to increased metabolism (Lakshmipathi & 
Jastremski 2005), there are also other factors that can affect weight gain in PLWHA.  HIV 
infection is frequently associated with malnutrition due to causes such as difficulties with 
eating (WHO 2002) and decreased absorption due to opportunistic infections (van der Hulst et 
al 1998).  Hence, it is crucial to investigate the disease symptoms experienced by PLWHA 
that can potentially affect their nutritional status.  In this study, the most predominant 
symptoms experienced among participants before supplementation was fever, followed by 
nausea and diarrhoea (past 2 weeks).  The predominance of fever is possibly caused by a 
compromised immune system due to infection as suggested by WHO (2002) and USAID 
(2001).   This predominance of fever is in line with the findings of Ahoua et al (2011) who 
also reported that the most frequently diagnosed opportunistic infections in PLWHA is fever 
of unknown aetiology.  There was a significant improvement in the incidence of fever 
between the first and the last visit (χ2=3.993, p<0.005).  Therefore, it is suggested that 
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Sibusiso® RUSF provided additional nutrients that improved the compromised immunity of 
participants due to infection and reduction in food intake.   
Other crucial findings from the study were an increase in the severity of all disease symptoms 
noticeable in the second visit.  However, the cause of that was unknown.  It should be noted 
that poverty and hunger prevail in this community, and these symptoms may be aggravated by 
side-effect from over-consuming RUSF due to a lack of any other available food.  This is 
even more specific to diarrhoea which is known to be aggravated by fat intake (WHO, FAO 
2002), as RUSF has a high fat content according to the nutritional information on the label 
(see Appendix A).  It is also possible that this suspected initial overdosing with RUSF could 
have been triggered by HIV stigma and perceiving RUSF as a fast method to overcome 
thinness which is a perceived obvious sign of HIV infection.   
Nausea and vomiting are common in PLWHA (WHO, FAO 2002).  Therefore a high 
percentage of participants with nausea (24%) was not surprising.  Based on the evidence that 
nausea can be caused by multiple factors including being a side effect, could also explain the 
increase in this symptom on the second visit.  As shown in Figure 4.3, from visit 1 to visit 4, 
there was a steady but significant decline in vomiting (χ2=11.937; p=0.001).  There was also a 
significant improvement in the incidence of gastroenteritis (χ2=6.648, p=0.05).  No 
change/improvement was shown in those who reported to have had chronic diarrhoea (two 
weeks prior to the clinic visit) when comparing the first and the last visit.  In a local study 
conducted on HIV positive breastfeeding mothers, RUSF did not make any impact on crude 
incidence of opportunistic infections, including diarrhoea (Kindra, Coutsoudis & Espisito 
2011).  This evidence is also crucial and in accord with the findings from this study where 
RUSF did not impact on reducing the prevalence of diarrhoea.   
According to Wilcox et al (2003), diarrhoea has a multitude of aetiologies with HIV itself 
being a potential cause.  Poor access to water (68%, n=34), indoor flushing toilet (16%, n=8) 
and fridges (54%, n=27) might have increased the risk of diarrhoea.  In addition, other daily 
consumed foods could be contaminated with diarrhoea-causing pathogens.  These findings 
indicate that the beneficial effects of Sibusiso® RUSF on eliminating symptoms and 
improving disease condition might be suppressed by other external factors, such as 
unhygienic drinking water.  Hence, a need for more intense education on personal hygiene is 
crucial.  MacArthur & DuPont (2012), Nel (2010) and Wilcox et al (2003) mentioned that the 
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interaction between diarrhoea and malnutrition is bidirectional. Diarrhoea leads to 
malnutrition while malnutrition exacerbates the increased risk of diarrhoea.  Breaking this 
cycle is therefore, very important to support good health.  
5.1.3. Appetite, meal consumption and energy levels improved among adults on ART and 
simultaneously supplemented with Sibusiso® RUSF. 
 
HIV/AIDS has been associated with loss of appetite (WHO, FAO 2002).  This was noticeable 
in the findings from this study.  The cause of loss of appetite was unknown but it is suspected 
that it is multifactorial, as a result of possible side-effects of the medication, as well as the 
high prevalence of fever reported at the first visit.  Fever and opportunistic infections reduce 
the intake of food in HIV positive patients by altering the patient’s appetite (USAID 2001).  
Patients also regularly experience smell and taste alterations with physical impairments in the 
oropharyngeal or oesophageal area, resulting in a loss of the desire to eat (Fenton & 
Silverman 2004).   This often requires medical intervention, using drugs that stimulate 
appetite.  GOTG (2010) claimed that Sibusiso® RUSF improved patient appetite.  However, 
this has been anecdotal.  In this study, an improvement in appetite was noted among 
participants throughout the duration of the study from the first to the fourth visit.   There was 
a dramatic change between the first two months of supplementation.  These findings confirm 
the results from other studies where RUSF use also improved appetite (Maharaj 2012; Maleta 
et al 2004; Manary et al 2004).  Saunders et al (2011) also stated that illness normally reduce 
appetite. There was a positive correlation between appetite level and meal consumption.  This 
suggests that as participants’ appetite improves the amount of food they consume also 
increase.  There was also a positive correlation between appetite levels and energy levels.   
Possible explanation for this finding could be the good appetite possible led to increased meal 
consumption, thus to better energy levels of the participants.  
 
An improvement in meal consumption was documented between the first and the last visit.  
The number of participants that were consuming a ¼ bowl of food had decreased while the 
number of subject that were consuming a full bowl increased.  Even though the number of 
participants consuming a ½ bowl decreased on the second visit and then increased steady in 
the following visits.  Overall improvement in illness (Saunders et al 2011) and fever in 
particular (USAID 2001), probably had an impact on improving meal consumption as these 
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have been suggested to affect food intake.  These findings are also in agreement with Maleta 
et al (2004) who reported that an improvement in appetite lead to an improvement in food 
intake.  Hence, it is speculated that the increase in appetite and disease-related symptoms 
observed during the period of supplementation contributed to increased meal consumption in 
the course of the study.  
 
GOTG (2010) claimed that Sibusiso® RUSF improves low energy levels, but this assumption 
was based on anecdotal evidence. A general improvement in energy levels was observed 
among participants monitored during the supplementation period in this current study.  As 
indicated in figure 4.6, at the end of the intervention period only 2% of the study population 
reported to be very weak. This is a substantial decrease from 26% of the participants who 
reported to feel very weak during the first visit.  Twenty-eight percent of the participants still 
felt weak during the last visit, which however represented a decrease from 70% of subjects 
who reported to feel weak during the first visit.  Collectively, 66% of the participants had a 
fair to full amount of energy in the last visit, which was an increase from 2% during the first 
visit.  Consumption of a well balanced diet is essential to provide energy that the body needs 
to maintain weight, fight infection and compromise for the elevated resting energy 
expenditure associated with HIV infection (WHO, FAO 2002).   When the body receives 
inadequate energy from food, it becomes weak and uses its muscle (lean body mass) for 
energy, which results in weight loss (WHO, FAO 2002).  Babameto & Kotler (1997) reported 
that weight loss is often the event that triggers a vicious cycle of increased fatigue and a 
decrease in physical activity, including the inability to prepare and consume food by 
PLWHA. There was a negative correlation between energy level of participants and their 
experience of disease symptoms such as gastroenteritis, fever and diarrhoea.   However, there 
is no overwhelming evidence to suggest that the presence of gastroenteritis, fever or persistent 
diarrhoea can sometimes compromise the energy levels of PLWHA.  The correlations were 
not very strong and were not identified throughout the course of the study but on certain 
visits, as seen in Table 4.4.  This is despite the suggestion that fever increases the demand for 
energy (WHO, FAO 2002) and alters appetite (USAIDS 2001), where as diarrhoea increase 






5.1.4 Body fat distribution in adults on ART after supplementation with Sibusiso® RUSF. 
 
HIV lipodystrophy can have adverse effects on PLWHA.  These include early onset 
hypercholesterolemia, CVD and DM (Domingo et al 2012).  Segatto et al (2012) reported that 
the HIV LDS causes are multifactorial, including a positive family history, current history of 
severe immune suppression, gender (especially females), the presence of opportunistic 
infections, AIDS diagnosis (stage 4 disease or CD4
+
 less than 200 cells/mm
3
) duration of 
HAART and type of HAART.  Especially stavudine (NRTI), ritonavir, and indinavir (PI) are 
prone to induce LDS.  Domingo et al (2012) stated that chronic ART can bring about 
additional metabolic side-effects, including dyslipidaemias, insulin resistance, and abnormal 
body fat re-distribution (lipodystrophy).  Overweight and obesity are common problems in 
PLWHA especially women (Segatto et al 2012).  If women are also associated with a high 
likelihood of developing HIV lipohypertrophy (Domingo et al 2012; Segatto et al 2012), this 
is cause for concern regarding the impact of RUSF if the results highlight its potential for the 
significant improvement in body weight.  Rossouw et al (2012) reported that there is a lack of 
data on the cost-effective measures to treat lipoatrophy and lipohypertrophy.  Therefore, 
prevention and sound scientific research on the potential causes remain important.  A 
prospective population-based study reported that an estimated 20% of individuals on HAART 
will experience fat redistribution in the first two years of treatment. In the current study, ten 
percent of the HIV positive participants suffered moderate lipohypertrophy,  five percent in 
the breast and the other five percent in the waist.  Ten percent other cases experienced severe 
hyperlipotrophy in the waist and abdomen.  However, no association between changes in BMI 
and the presence of lipoatrophy or lipohypertrophy were measured.  It can therefore be 
concluded that it is highly unlikely that the presence of lipodystrophy in this study population 
has not been affected by short-term supplementation with RUSF.  However, it is suspected 
that the presence of lipodystrophy in this study population can be ascribed to the other factors, 
such as those mentioned previously.  Furthermore, no similar studies were found of which the 
results of this study could be compared to.  This serves as a motivation for further study, 







5.2   Shortcomings of the study 
The shortcoming of this study included the following: 
 Both genders were not equally represented in the study:  the majority of men were not 
compliant to participate, as their visits were inconsistent, non-consecutive and they 
withdrew early.  Assessment of attitude and perception towards supplementation 
programmes should be considered in future studies;   
 The frequency of intake of certain foods was measured. The foods used were the 
commonly used foods in KwaZulu-natal rural areas and there are a representative of all 
food groups.  However, it was not possible to quantify the exact nutrient intakes, which 
would have provided a more comprehensive understanding of dietary habits of the 
population group.  A diet history could have served as an appropriate tool for this 
purpose; 
 This study did not include the use of a placebo, as it is not an ethical choice; 
 Macallan (1999) documented that therapeutic strategies do not reverse depletion of 
LBM, but instead have been reported to mainly increase body fat and water.  A loss of 
lean body mass is a prognostic marker in HIV infection and changes in body 
composition are more sensible in testing intervention outcomes. Weight gain in this 
study could not be classified, based on whether it is associated with a desirable gain in 
lean body mass or undesirable increase in body fat; 
 Additional follow-up visits of participants should be conducted to observe whether the 
weight gain and improvement in disease symptoms were sustainable;  
 The assessments of body/morphological changes were conducted on only a small 
number of participants. It is suggested that the study should be repeated using a much 
larger study sample. 
 Future studies should assess the impact of RUSF by also including changes in blood 









The aim of this study was to determine the impact of a locally produced ready-to-use 
supplementary food, Sibusiso®, on BMI and on the improvement of disease symptoms 
identified at baseline assessment of HIV positive adults receiving ART.  It also aimed to 
determine the impact of this supplementary food on lipodystrophy in HIV positive adults 
receiving ART.  In this chapter, the main conclusions of this study and implications for future 
research will be discussed.   
 
6.1 Conclusion 
Within the context of the hypotheses stated in Chapter 1 of this thesis, the following 
conclusions can be made: 
 The administration of the nutrition supplement Sibusiso® RUSF, in conjunction with 
the use of ART, might increase the likelihood of nutritional recovery in malnourished 
HIV patients.  Findings from this study support the hypothesis that supplementation 
with RUSF at least for three months has the potential to gradually improve BMI among 
HIV-positive adults on ART in clinical settings.  RUSF is high in energy and 
supplementation with it likely contributes to an improved energy intake, even though it 
is unable to meet full RDA requirements for either energy or macronutrients. This study 
reported no association between the starting weight and BMI changes after three months 
of supplementation.  It is hypothesised that in this finding lies a possible benefit, in the 
sense that Sibusiso® RUSF can be used effectively in patients with HIV, regardless of 
their BMI.  It is not certain whether this also holds true for the different stages of 
disease progression, as it has been reported that disease progression influences 
treatment outcome, also in terms of ART. This is the basis for the decision of local 
authorities to start treatment at an earlier phase of disease progression (DoH 2010). 
 The most predominant disease symptom and disease conditions experienced by the 
subject population before supplementation was initiated, were fever followed by nausea 
and persistent diarrhoea.  Fever was unexpected but the predominance of nausea and 
diarrhoea support the hypothesis that the contamination of the environment in poor 
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communities increases the risk of PLWHA to contract these symptoms.  No support 
however was found for the hypothesis that vomiting predominated.  The predominance 
of the earlier mentioned symptoms was also keeping with the results from other 
previous studies.   
 Unexpectedly, participants reported an increase in severity of these symptoms from the 
baseline to the second visit, but the reason for this finding was unknown. However, it is 
suspected that overconsumption of the supplement could have contributed to possible 
side-effects.  Reason for overconsumption could be a lack of other available food 
sources due to poverty or perceiving RUSF as a fast method to overcome the stigma 
associated with thinness.  Yet, the increased presence of some of the symptoms could 
possibly have metabolic origins, similar to that when a patient with HIV commences 
ART.  However, but this is purely based on speculation.   
 There was a significant and beneficial improvement in fever and gastroenteritis; steady 
but significant decline in vomiting and no change in persistent diarrhoea, from the 
beginning of supplementation to subsequent visits.  The findings of this current study 
support the hypothesis that supplementation with the RUSF will provides participants 
with more nutrients that will help in the improvement of symptoms experienced by 
participants. Despite the low water content of RUSF combined with a low risk of 
contamination with pathogens, intense education on personal hygiene is crucial to break 
the cycle of diarrhoea and malnutrition in people infected with HIV, especially in 
poverty stricken areas. 
 Other conditions such as lack of appetite and fatigue were present at the beginning of 
supplementation.  Loss of appetite was probably a result of fever or alteration of taste 
and smell due to illness.  In this study Sibusiso® RUSF was also found to exert a 
beneficial effect on appetite, meal consumption and energy levels of participants.   
These results support the hypothesis that because of the high nutrient and energy density 
of Sibusiso® RUSF, there will be improvement in these conditions in participants 
receiving supplementation.  Even at the second visit when participants reported an 
increase in disease symptoms, they also reported an improvement in appetite, meal 
consumption and energy levels.  These three factors are expected to complement each 
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other in order to improve nutritional status in this population group, if it is assumed that 
the individuals have access to appropriate food and supplements such as RUSF. 
 Lipodystrophy was reported by 20% HIV positive participants who were receiving 
Sibusiso® RUSF for three months.  However, one cannot unreservedly reject the 
hypothesis that Sibusiso® RUSF will not induce lipodystrophy.  It is highly unlikely in 
this study, that lipodystrophy in the participants were affected by supplementation with 
RUSF.  Yet, it is uncertain whether these results are conclusive, in the sense that it 
requires more long-term epidemiological studies to see whether RUSF-induced weight 
gain, is associated with an improvement in lean body mass, or whether the weight gain 
is as a result of increased body fat stores, which is not desirable. 
In conclusion, Sibusiso® RUSF was not only successful in promoting weight gain among 
participants, but was also able to improve the overall wellbeing of participants by alleviating 
the burden of disease conditions and infectious symptoms while improving appetite, meal 
consumption and energy levels without inducing any morphological changes.  It is therefore 
important to consider scaling up the RUSF intervention at the same pace as ART programs in 
high HIV prevalence areas dominated by poverty and malnutrition. 
 
6.2   Implications for further research 
 
The administration of the nutrition supplement Sibusiso® RUSF, in conjunction with the use 
of ART, might increase the chances of nutritional recovery in malnourished HIV patients. 
Findings from this study suggest that supplementation with RUSF for at least three months 
has the potential to gradually improve weight gain among HIV-positive adults under ART in 
the clinical settings.  It is suggested that future research investigates whether Sibusiso® 
supplementation sustains weight gain in HIV positive patients for longer periods of time. If 
so, then the use of Sibusiso® should be promoted, especially in areas of low socio-economic 
status where the prevalence of HIV has reached epidemic proportion. Yet, it remains a 
priority to investigate whether Sibusiso® promotes an increase in body fat stores, or whether 
it promotes an improvement in lean body mass, as this would finally establish whether the 
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